Methotrexate
(Synonyms: Amethopterin; CL14377; WR19039)
80 Cited Publications
Avis client
Based on 80 publication(s) in Google Scholar
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 59-05-2
- Formule: C20H22N8O5
- Masse moléculaire:454.44
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Methotrexate
More- Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Adv Mater. 2025 Dec 12:e13952. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
- J Adv Res. 2025 Aug:74:609-620. [Abstract]
- Redox Biol. 2025 Feb:79:103482. [Abstract]
- J Nanobiotechnology. 2024 Mar 3;22(1):89. [Abstract]
- J Exp Clin Cancer Res. 2024 Dec 26;43(1):330. [Abstract]
- J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Mol Biomed. 2025 Nov 21;6(1):114. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):852. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):856. [Abstract]
- Cell Death Dis. 2024 May 20;15(5):349. [Abstract]
- Cell Death Dis. 2020 Nov 12;11(11):976. [Abstract]
- Small. 2022 Jul;18(30):e2202337. [Abstract]
- Phytomedicine. 2026 Jan:150:157731. [Abstract]
- Phytomedicine. 2022 Jun;100:154068. [Abstract]
- J Pharm Anal. 2022 Dec;12(6):879-888. [Abstract]
- Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. [Abstract]
- Acta Pharmacol Sin. 2025 Jun;46(6):1733-1741. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Biomater Res. 2025 Sep 3:29:0245. [Abstract]
- EMBO Mol Med. 2025 Oct 13. [Abstract]
- EMBO Mol Med. 2022 Mar 7;14(3):e14552. [Abstract]
- Cell Rep. 2025 Mar 25;44(4):115466. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Sci Signal. 2024 Nov 26;17(864):eadp1375. [Abstract]
- J Ethnopharmacol. 2026 Apr 24:361:121230. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Cells. 2026 Jun 11;15(12):1070. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Commun Biol. 2022 Jun 23;5(1):619. [Abstract]
- Eur J Pharmacol. 2023 Dec 15:961:176162. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114894. [Abstract]
- Int Immunopharmacol. 2025 May 27:156:114735. [Abstract]
- Int Immunopharmacol. 2024 Jun 15:134:112183. [Abstract]
- Int Immunopharmacol. 2023 Nov 15;125(Pt B):111175. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109689. [Abstract]
- Arthritis Res Ther. 2022 Jan 19;24(1):27. [Abstract]
- ACS Omega. 2026 Jan 21;11(4):5853-5864. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Toxicology. 2020 May 15:437:152445. [Abstract]
- Eur J Pharm Sci. 2025 Nov 1:214:107296. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Mediators Inflamm. 2024 Dec 5:2024:1995952. [Abstract]
- Sci Rep. 2024 Oct 31;14(1):26224. [Abstract]
- Sci Rep. 2018 Jun 21;8(1):9472. [Abstract]
- Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
- Cancers. 2019 Oct 25;11(11):1654. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Rheumatology (Oxford). 2025 Aug 13:keaf437. [Abstract]
- Antiviral Res. 2026 Jun:250:106417. [Abstract]
- Lung. 2024 Nov 27;203(1):4. [Abstract]
- Antimicrob Agents Chemother. 2026 Jul;70(7):e0196025. [Abstract]
- Chem Res Toxicol. 2025 Feb 17;38(2):281-295. [Abstract]
- J Biol Chem. 2019 Dec 27;294(52):20084-20096. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Mol Immunol. 2025 Apr 16:182:83-95. [Abstract]
- Dis Model Mech. 2023 Mar 1;16(3):dmm049769. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Micromachines. 2021 Jun 10;12(6):681. [Abstract]
- Biochem Biophys Rep. 2021 Nov 26:28:101177. [Abstract]
- Plasma Process Polym. 2021 Feb 12.
- Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251348715. [Abstract]
- Anticancer Res. 2024 Oct;44(10):4213-4218. [Abstract]
- Anticancer Res. 2024 Jul;44(7):2787-2792. [Abstract]
- bioRxiv. 2026 May 6.
- bioRxiv. 2025 Nov 20.
- SSRN. 2025 Oct 10.
- Patent. US20250235423A1.
- Authorea. 2025 Jan 03.
- Guidelines and Standards in Chinese Medicine. 2024 Dec.
- Biomed Pharmacother. 2024 Sep:178:117167. [Abstract]
- Research Square Preprint. 2023 Dec 4.
- Research Square Preprint. 2023 Dec 1.
- Queen’s University. 2021 Oct.
- Oncotarget. 2017 Dec 2;8(68):112313-112329. [Abstract]
- Patent. US20170128439A1.
Customer Validation & Images
Cell Imaging/StainingCell Proliferation/Viability AssayRT-PCRCell Migration/Invasion Assay
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
Activité biologique
Description
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer[1][2][3][4][5].
IC50 & Target
|
COX-2 |
IL-8 |
iNOS |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 143B | IC50 |
8.8 nM
Compound: MTX
|
Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
|
[PMID: 8632413] |
| 5637 | IC50 |
0.016 μM
Compound: Methotrexate
|
Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining
Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| 786-0 | IC50 |
33 nM
Compound: MTX (1)
|
The IC50 value was measured on 786-0 cell line in renal tumor type.
The IC50 value was measured on 786-0 cell line in renal tumor type.
|
[PMID: 9022795] |
| 786-0 | IC50 |
33 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
|
[PMID: 9857098] |
| A-375 | IC50 |
0.022 μM
Compound: Methotrexate
|
Antiproliferative activity against human A375 cells
Antiproliferative activity against human A375 cells
|
[PMID: 27217001] |
| A-427 | IC50 |
5.52 μM
Compound: Methotrexate
|
Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining
Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| A498 | IC50 |
0.022 μM
Compound: Methotrexate
|
Antiproliferative activity against human A498 cells
Antiproliferative activity against human A498 cells
|
[PMID: 27217001] |
| A498 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
|
[PMID: 9857098] |
| A549 | IC50 |
0.005 μg/mL
Compound: ametropterin
|
Antitumor activity against human A549 cells
Antitumor activity against human A549 cells
|
[PMID: 10579858] |
| A549 | IC50 |
0.02 μM
Compound: 1a, MTX
|
Antiproliferative activity against A549 cells after 72 hrs in folate depleted media
Antiproliferative activity against A549 cells after 72 hrs in folate depleted media
|
[PMID: 17127067] |
| A549 | IC50 |
0.1 μM
Compound: 1a, MTX
|
Antiproliferative activity against A549 cells after 72 hrs by MTT assay
Antiproliferative activity against A549 cells after 72 hrs by MTT assay
|
[PMID: 17127067] |
| A549 | IC50 |
35 ng/mL
Compound: Methotrexate
|
In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells.
In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells.
|
[PMID: 1847428] |
| A549 | IC50 |
37.4 nM
Compound: 1, MTX
|
Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method
Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method
|
[PMID: 20036565] |
| A549 | IC50 |
5 nM
Compound: MTX
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 20580561] |
| A549 | IC50 |
0.013 μM
Compound: MTX
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25668494] |
| A549 | IC50 |
0.99 μM
Compound: MTX
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay in presence of leucovorin
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay in presence of leucovorin
|
[PMID: 27017552] |
| A549 | IC50 |
0.022 μM
Compound: Methotrexate
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 27217001] |
| A549 | IC50 |
0.25 μM
Compound: MTX
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27886545] |
| A549 | IC50 |
0.0135 μM
Compound: MTX
|
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 28152430] |
| A549 | GI50 |
0.014 μM
Compound: MTX
|
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| A549 | IC50 |
39.33 μg/mL
Compound: MTX
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 30554970] |
| A549 | IC50 |
990 nM
Compound: MTX
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31200235] |
| A549 | IC50 |
0.014 μM
Compound: MTX
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 32058237] |
| A549 | IC50 |
31 nM
Compound: MTX
|
Cytotoxic activity evaluated against A549 tumor cells
Cytotoxic activity evaluated against A549 tumor cells
|
[PMID: 8632413] |
| A549 | IC50 |
23 nM
Compound: MTX (1)
|
In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
|
[PMID: 9022795] |
| A549 | IC50 |
33 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| ACHN | IC50 |
40 nM
Compound: MTX (1)
|
The IC50 value was measured on ACHN cell line in renal tumor type.
The IC50 value was measured on ACHN cell line in renal tumor type.
|
[PMID: 9022795] |
| ACHN | IC50 |
40 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
|
[PMID: 9857098] |
| Bel-7402 | IC50 |
82.3 μM
Compound: MTX
|
Cytotoxicity against human Bel7402 cells after 48 hrs
Cytotoxicity against human Bel7402 cells after 48 hrs
|
[PMID: 18555562] |
| BGC-823 | IC50 |
0.11 μM
Compound: MTX
|
Cytotoxicity against human BGC823 cells after 48 hrs
Cytotoxicity against human BGC823 cells after 48 hrs
|
[PMID: 18555562] |
| BT-549 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against BT-549 breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against BT-549 breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| Caco-2 | EC50 |
1.1 μM
Compound: Methotrexate
|
Cytotoxicity against human Caco-2 cells assessed as cell viability by XTT assay
Cytotoxicity against human Caco-2 cells assessed as cell viability by XTT assay
|
[PMID: 20674353] |
| Caco-2 | IC50 |
0.32 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay
Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay
|
[PMID: 20846760] |
| Caco-2 | IC50 |
0.32 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human Caco2 cells after 48 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 48 hrs by MTT assay
|
10.1007/s00044-013-0773-3 |
| CAKI-1 | IC50 |
>60 μg/mL
Compound: methotrexate
|
Growth inhibition of human CAKI1 cells after 72 hrs
Growth inhibition of human CAKI1 cells after 72 hrs
|
[PMID: 17569517] |
| CAKI-1 | IC50 |
25 μg/mL
Compound: MTX
|
Inhibition of colony formation of Caki-1 cells by MTX
Inhibition of colony formation of Caki-1 cells by MTX
|
[PMID: 2810330] |
| CAKI-1 | IC50 |
3 μg/mL
Compound: MTX
|
Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20
Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20
|
[PMID: 2810330] |
| CAKI-1 | IC50 |
3.3 μg/mL
Compound: MTX
|
Inhibition of colony formation of Caki-1 cells by amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20
Inhibition of colony formation of Caki-1 cells by amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20
|
[PMID: 2810330] |
| CAKI-1 | IC50 |
3.4 μg/mL
Compound: MTX
|
Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate of MTX and Dal K-20
Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate of MTX and Dal K-20
|
[PMID: 2810330] |
| CAKI-1 | IC50 |
4.5 μg/mL
Compound: MTX
|
Inhibition of colony formation of Caki-1 cells by amide-linked conjugate of MTX and Dal K-20
Inhibition of colony formation of Caki-1 cells by amide-linked conjugate of MTX and Dal K-20
|
[PMID: 2810330] |
| Cancer cell lines | IC50 |
2.4 μM
Compound: Methotrexate
|
Anticancer activity against human NCI lung cancer cell by MTT assay
Anticancer activity against human NCI lung cancer cell by MTT assay
|
[PMID: 27112448] |
| Cancer cell lines | IC50 |
2.2 μM
Compound: Methotrexate
|
Anticancer activity against Homo sapiens (human) NCI lung cancer cell assessed as inhibition of cell proliferation after 24 hr by MTT assay
Anticancer activity against Homo sapiens (human) NCI lung cancer cell assessed as inhibition of cell proliferation after 24 hr by MTT assay
|
10.1007/s00044-012-0260-2 |
| carcinoma cell line | EC50 |
13.8 nM
Compound: MTX
|
Tested for their inhibition of growth of CCRF-CEM human leukemia on carcinoma cell lines.
Tested for their inhibition of growth of CCRF-CEM human leukemia on carcinoma cell lines.
|
[PMID: 11052789] |
| carcinoma cell line | EC50 |
14.5 nM
Compound: MTX
|
Tested for their inhibition of growth of FaDu head on carcinoma cell lines.
Tested for their inhibition of growth of FaDu head on carcinoma cell lines.
|
[PMID: 11052789] |
| CCRF S-180 | IC50 |
0.0054 μM
Compound: MTX
|
Concentration required for 50% inhibition against S180 cells
Concentration required for 50% inhibition against S180 cells
|
[PMID: 6403710] |
| CCRF S-180 | ED50 |
0.016 μM
Compound: methotrexate
|
Cytotoxic activity against the S180 cell cultures
Cytotoxic activity against the S180 cell cultures
|
[PMID: 6928967] |
| CCRF S-180 | IC50 |
10 nM
Compound: MTX
|
Tested for the ability to inhibit growth in vitro against S180 cells
Tested for the ability to inhibit growth in vitro against S180 cells
|
[PMID: 8277497] |
| CCRF-CEM | EC50 |
14.4 nM
Compound: MTX
|
Growth inhibition of CCRF-CEM human leukemia cells.
Growth inhibition of CCRF-CEM human leukemia cells.
|
[PMID: 10956221] |
| CCRF-CEM | EC50 |
13.8 nM
Compound: MTX
|
Concentration required to inhibit growth against CCRF-CEM cell
Concentration required to inhibit growth against CCRF-CEM cell
|
[PMID: 11052789] |
| CCRF-CEM | EC50 |
15.5 nM
Compound: MTX
|
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease polyglutamylation.
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease polyglutamylation.
|
[PMID: 11052789] |
| CCRF-CEM | EC50 |
2030 nM
Compound: MTX
|
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease in uptake.
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease in uptake.
|
[PMID: 11052789] |
| CCRF-CEM | EC50 |
660 nM
Compound: MTX
|
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of increase in wild type DHFR protein and activity.
Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of increase in wild type DHFR protein and activity.
|
[PMID: 11052789] |
| CCRF-CEM | EC50 |
14 nM
Compound: Methotrexate(MTX)
|
Growth inhibition of parental CCRF-CEM cells.
Growth inhibition of parental CCRF-CEM cells.
|
[PMID: 11384244] |
| CCRF-CEM | EC50 |
15 nM
Compound: Methotrexate(MTX)
|
Growth inhibition of CCRF-CEM cells resistant to MTX
Growth inhibition of CCRF-CEM cells resistant to MTX
|
[PMID: 11384244] |
| CCRF-CEM | EC50 |
1900 nM
Compound: Methotrexate(MTX)
|
Growth inhibition of DHFR-uptake, defined mechanisms of MTX resistance during continuous (0-120 h) exposure
Growth inhibition of DHFR-uptake, defined mechanisms of MTX resistance during continuous (0-120 h) exposure
|
[PMID: 11384244] |
| CCRF-CEM | EC50 |
600 nM
Compound: Methotrexate(MTX)
|
Growth inhibition of DHFR-overexpressing cells, defined mechanisms of MTX resistance during continuous (0-120 h) exposure
Growth inhibition of DHFR-overexpressing cells, defined mechanisms of MTX resistance during continuous (0-120 h) exposure
|
[PMID: 11384244] |
| CCRF-CEM | IC50 |
0.004 μg/mL
Compound: MTX
|
Compound was tested for cytotoxic activity in CCRF-CEM Human Leukemia cells by in vitro cytotoxicity assay
Compound was tested for cytotoxic activity in CCRF-CEM Human Leukemia cells by in vitro cytotoxicity assay
|
[PMID: 11428931] |
| CCRF-CEM | EC50 |
14.5 nM
Compound: MTX
|
Inhibition of growth of CCRF-CEM human leukemia cells (n=4)
Inhibition of growth of CCRF-CEM human leukemia cells (n=4)
|
[PMID: 11960504] |
| CCRF-CEM | EC50 |
12 nM
Compound: MTX
|
Concentration required to decrease cell growth by 50% in CCRF-CEM human leukemia cell line
Concentration required to decrease cell growth by 50% in CCRF-CEM human leukemia cell line
|
[PMID: 12408727] |
| CCRF-CEM | EC50 |
16 nM
Compound: MTX
|
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R30dm)
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R30dm)
|
[PMID: 12408727] |
| CCRF-CEM | EC50 |
1700 nM
Compound: MTX
|
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R2)
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R2)
|
[PMID: 12408727] |
| CCRF-CEM | EC50 |
595 nM
Compound: MTX
|
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R1)
Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R1)
|
[PMID: 12408727] |
| CCRF-CEM | EC50 |
13.7 nM
Compound: Methotrexate
|
Growth inhibition of CCRF-CEM Human Leukemia Cell was determined
Growth inhibition of CCRF-CEM Human Leukemia Cell was determined
|
[PMID: 12570380] |
| CCRF-CEM | EC50 |
16.5 nM
Compound: MTX
|
Growth inhibition of MTX-resistant human CCRF-CEM R30dm cells
Growth inhibition of MTX-resistant human CCRF-CEM R30dm cells
|
[PMID: 15615522] |
| CCRF-CEM | EC50 |
17.5 nM
Compound: MTX
|
Growth inhibition of human CCRF-CEM cells
Growth inhibition of human CCRF-CEM cells
|
[PMID: 15615522] |
| CCRF-CEM | EC50 |
1500 nM
Compound: MTX
|
Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs
Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs
|
[PMID: 15615538] |
| CCRF-CEM | EC50 |
660 nM
Compound: MTX
|
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs
|
[PMID: 15615538] |
| CCRF-CEM | EC50 |
7.9 nM
Compound: MTX
|
Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs
Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs
|
[PMID: 15615538] |
| CCRF-CEM | EC50 |
8.2 nM
Compound: MTX
|
Growth inhibition of human CCRF-CEM cells
Growth inhibition of human CCRF-CEM cells
|
[PMID: 15615538] |
| CCRF-CEM | EC50 |
13 nM
Compound: Methotrexate
|
Growth inhibitory activity against CCRF-CEM human lymphoblastic leukemia cells
Growth inhibitory activity against CCRF-CEM human lymphoblastic leukemia cells
|
[PMID: 16078850] |
| CCRF-CEM | EC50 |
14.5 nM
Compound: Methotrexate
|
Growth inhibitory activity against MTX resistant CCRF-CEM human lymphoblastic leukemia cells with decreased polyglutamylation
Growth inhibitory activity against MTX resistant CCRF-CEM human lymphoblastic leukemia cells with decreased polyglutamylation
|
[PMID: 16078850] |
| CCRF-CEM | EC50 |
1500 nM
Compound: Methotrexate
|
Growth inhibitory activity against resistant CCRF-CEM human lymphoblastic leukemia cells with decreased uptake of MTX
Growth inhibitory activity against resistant CCRF-CEM human lymphoblastic leukemia cells with decreased uptake of MTX
|
[PMID: 16078850] |
| CCRF-CEM | EC50 |
620 nM
Compound: Methotrexate
|
Growth inhibitory activity against MTX resistant subline of CCRF-CEM human lymphoblastic leukemia cells
Growth inhibitory activity against MTX resistant subline of CCRF-CEM human lymphoblastic leukemia cells
|
[PMID: 16078850] |
| CCRF-CEM | EC50 |
12.5 nM
Compound: MTX
|
Growth inhibition of human CCRF-CEM cells
Growth inhibition of human CCRF-CEM cells
|
[PMID: 16279780] |
| CCRF-CEM | EC50 |
14.5 nM
Compound: MTX
|
Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs
Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs
|
[PMID: 16279780] |
| CCRF-CEM | EC50 |
1500 nM
Compound: MTX
|
Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs
Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs
|
[PMID: 16279780] |
| CCRF-CEM | EC50 |
615 nM
Compound: MTX
|
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs
|
[PMID: 16279780] |
| CCRF-CEM | EC50 |
14 nM
Compound: MTX
|
Inhibition of growth in CCRF-CEM cells
Inhibition of growth in CCRF-CEM cells
|
[PMID: 16451071] |
| CCRF-CEM | EC50 |
17 nM
Compound: MTX
|
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R30dm cells
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R30dm cells
|
[PMID: 16451071] |
| CCRF-CEM | EC50 |
13.3 nM
Compound: Methotrexate, MTX
|
Growth inhibition of human CCRF-CEM cells
Growth inhibition of human CCRF-CEM cells
|
[PMID: 17552508] |
| CCRF-CEM | EC50 |
15.7 nM
Compound: Methotrexate, MTX
|
Growth inhibition of of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of FPGS
Growth inhibition of of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of FPGS
|
[PMID: 17552508] |
| CCRF-CEM | EC50 |
1950 nM
Compound: Methotrexate, MTX
|
Growth inhibition of human CCRF-CEM R2 cells with low methotrexate uptake
Growth inhibition of human CCRF-CEM R2 cells with low methotrexate uptake
|
[PMID: 17552508] |
| CCRF-CEM | EC50 |
410 nM
Compound: Methotrexate, MTX
|
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overexpressing DHFR
Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overexpressing DHFR
|
[PMID: 17552508] |
| CCRF-CEM | EC50 |
12.5 nM
Compound: methotrexate, MTX
|
Cytotoxicity against human CCRF-CEM cells
Cytotoxicity against human CCRF-CEM cells
|
[PMID: 18605720] |
| CCRF-CEM | IC50 |
0.032 μM
Compound: 1 (MTX)
|
Tested for cell-growth inhibition against human leukemic lymphoblast CEM cells
Tested for cell-growth inhibition against human leukemic lymphoblast CEM cells
|
[PMID: 2898531] |
| CCRF-CEM | IC50 |
6.6 μM
Compound: 1 (MTX)
|
Tested for cell-growth inhibition against human leukemic lymphoblast CEM/MTX cells
Tested for cell-growth inhibition against human leukemic lymphoblast CEM/MTX cells
|
[PMID: 2898531] |
| CCRF-CEM | IC50 |
0.032 μM
Compound: MTX
|
Cell growth inhibition against CEM cell from human leukemic lymphoblasts
Cell growth inhibition against CEM cell from human leukemic lymphoblasts
|
[PMID: 3872941] |
| CCRF-CEM | IC50 |
6.6 μM
Compound: MTX
|
Cell growth inhibition against CEM/MTX cell from human leukemic lymphoblasts
Cell growth inhibition against CEM/MTX cell from human leukemic lymphoblasts
|
[PMID: 3872941] |
| CCRF-CEM | IC50 |
0.025 μM
Compound: MTX
|
In vitro cytotoxicity by its growth inhibitory activity against human leukemic lymphoblasts (CEM cells).
In vitro cytotoxicity by its growth inhibitory activity against human leukemic lymphoblasts (CEM cells).
|
[PMID: 6585550] |
| CCRF-CEM | EC50 |
0.014 μM
Compound: MTX
|
Growth inhibition against Human leukemic cell line(CCRF-CEM)
Growth inhibition against Human leukemic cell line(CCRF-CEM)
|
[PMID: 7473577] |
| CCRF-CEM | EC50 |
0.018 μM
Compound: MTX
|
Growth inhibition against Human leukemic cell line (Methotrexate resistant CCRF-CEM)
Growth inhibition against Human leukemic cell line (Methotrexate resistant CCRF-CEM)
|
[PMID: 7473577] |
| CCRF-CEM | EC50 |
0.014 μM
Compound: MTX
|
he compound was tested for Growth inhibition of the Human T-lymphoblastic Leukemia cell line CCRF-CEM
he compound was tested for Growth inhibition of the Human T-lymphoblastic Leukemia cell line CCRF-CEM
|
[PMID: 7562910] |
| CCRF-CEM | EC50 |
0.018 μM
Compound: MTX
|
The compound was tested for Growth inhibition of Methotrexate-resistant human T-lymphoblastic leukemia cell line CCRF-CEM(sub line R30dm)
The compound was tested for Growth inhibition of Methotrexate-resistant human T-lymphoblastic leukemia cell line CCRF-CEM(sub line R30dm)
|
[PMID: 7562910] |
| CCRF-CEM | IC50 |
0.0007 μM
Compound: MTX
|
Inhibitory concentration against CCRF-CEM leukemic cell DHFR(Dihydro folate reductase).
Inhibitory concentration against CCRF-CEM leukemic cell DHFR(Dihydro folate reductase).
|
[PMID: 7562910] |
| CCRF-CEM | IC50 |
0.7 nM
Compound: MTX
|
Inhibitory concentration against CCRF-CEM leukemic cell DHFR(Dihydro folate reductase).
Inhibitory concentration against CCRF-CEM leukemic cell DHFR(Dihydro folate reductase).
|
[PMID: 7562910] |
| CCRF-CEM | EC50 |
14.5 nM
Compound: MTX
|
Compound was evaluated for the growth inhibition of parental CCRF-CEM
Compound was evaluated for the growth inhibition of parental CCRF-CEM
|
[PMID: 7783147] |
| CCRF-CEM | EC50 |
14.5 nM
Compound: MTX
|
Compound was evaluated for the growth inhibition of R30dm, a CCRF-CEM subline resistant to intermittent MTX exposure solely as a result of decreased polyglutamylation.
Compound was evaluated for the growth inhibition of R30dm, a CCRF-CEM subline resistant to intermittent MTX exposure solely as a result of decreased polyglutamylation.
|
[PMID: 7783147] |
| CCRF-CEM | EC50 |
3100 nM
Compound: MTX
|
Compound was evaluated for the growth inhibition of R2, a CCRF-CEM subline resistant to MTX as a result of deffective uptake.
Compound was evaluated for the growth inhibition of R2, a CCRF-CEM subline resistant to MTX as a result of deffective uptake.
|
[PMID: 7783147] |
| CCRF-CEM | EC50 |
595 nM
Compound: MTX
|
Compound was evaluated for the growth inhibition of R1, a CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity
Compound was evaluated for the growth inhibition of R1, a CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity
|
[PMID: 7783147] |
| CCRF-CEM | IC50 |
10.5 nM
Compound: MTX
|
Tested for inhibitory concentration of cell growth against CCRF-CEM cell lines of human leukemic lymphoblast
Tested for inhibitory concentration of cell growth against CCRF-CEM cell lines of human leukemic lymphoblast
|
[PMID: 8035423] |
| CCRF-CEM | IC50 |
2550 nM
Compound: MTX
|
Tested for inhibitory concentration of cell growth against CEM/MTX cell lines of human leukemic lymphoblast
Tested for inhibitory concentration of cell growth against CEM/MTX cell lines of human leukemic lymphoblast
|
[PMID: 8035423] |
| CCRF-CEM | EC50 |
16 nM
Compound: MTX
|
the growth inhibition of, (during continuous exposure) human T-lymphoblastic leukemia cell line CCRF-CEM at resistance mechanism- sensitive
the growth inhibition of, (during continuous exposure) human T-lymphoblastic leukemia cell line CCRF-CEM at resistance mechanism- sensitive
|
[PMID: 8164259] |
| CCRF-CEM | EC50 |
2760 nM
Compound: MTX
|
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline CEM/MTX at resistance mechanism - decreased influx
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline CEM/MTX at resistance mechanism - decreased influx
|
[PMID: 8164259] |
| CCRF-CEM | ED50 |
13.7 nM
Compound: MTX
|
Compound was evaluated for growth inhibition of parental CCRF-CEM during continuous (120 h) exposure to MTX
Compound was evaluated for growth inhibition of parental CCRF-CEM during continuous (120 h) exposure to MTX
|
[PMID: 8568828] |
| CCRF-CEM | ED50 |
15.5 nM
Compound: MTX
|
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased polyglutamylation during continuous (120 h) exposure.
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased polyglutamylation during continuous (120 h) exposure.
|
[PMID: 8568828] |
| CCRF-CEM | ED50 |
2550 nM
Compound: MTX
|
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased MTX influx during continuous (120 h) exposure.
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased MTX influx during continuous (120 h) exposure.
|
[PMID: 8568828] |
| CCRF-CEM | ED50 |
655 nM
Compound: MTX
|
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of a 25-fold increase in wild-type DHFR activity during continuous (120 h) exposure to MTX
Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of a 25-fold increase in wild-type DHFR activity during continuous (120 h) exposure to MTX
|
[PMID: 8568828] |
| CCRF-CEM | IC50 |
0.72 μM
Compound: MTX
|
Inhibitory activity against purified human dihydrofolate reductase (DHFR) in human leukemia cells (CCRF-CEM)
Inhibitory activity against purified human dihydrofolate reductase (DHFR) in human leukemia cells (CCRF-CEM)
|
[PMID: 8568828] |
| CCRF-CEM | IC50 |
14.5 μM
Compound: MTX
|
Inhibitory activity against uptake of [3H]-MTX at Folyl-polyglutamate synthase by human leukemia cells (CCRF-CEM)
Inhibitory activity against uptake of [3H]-MTX at Folyl-polyglutamate synthase by human leukemia cells (CCRF-CEM)
|
[PMID: 8568828] |
| CCRF-CEM | ED50 |
14.5 nM
Compound: MTX
|
Inhibitory activity against growth of CCRF-CEM human leukemia cells.
Inhibitory activity against growth of CCRF-CEM human leukemia cells.
|
[PMID: 8691451] |
| CCRF-CEM | IC50 |
0.82 nM
Compound: MTX
|
Inhibitory concentration against dihydrofolate reductase (DHFR) enzyme isolated from CCRF-CEM human leukemia cells.
Inhibitory concentration against dihydrofolate reductase (DHFR) enzyme isolated from CCRF-CEM human leukemia cells.
|
[PMID: 8691451] |
| CCRF-CEM | IC50 |
3.2 μM
Compound: MTX (Methotrexate)
|
Compound was evaluated for the inhibitory activity against Folyl-polyglutamate synthase from CCRF-CEM human leukemia cells.
Compound was evaluated for the inhibitory activity against Folyl-polyglutamate synthase from CCRF-CEM human leukemia cells.
|
[PMID: 8863812] |
| CCRF-CEM | EC50 |
14.3 nM
Compound: MTX
|
Growth inhibition was measured as for inhibition of growth in CCRF-CEM cells.
Growth inhibition was measured as for inhibition of growth in CCRF-CEM cells.
|
[PMID: 9554874] |
| CCRF-CEM | EC50 |
567 nM
Compound: MTX
|
Growth inhibition was measured for inhibition of growth in CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity.
Growth inhibition was measured for inhibition of growth in CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity.
|
[PMID: 9554874] |
| CCRF-CEM | EC50 |
8 nM
Compound: MTX
|
Growth inhibition was measured for inhibition of growth in CCRF-CEM sublines resistant to MTX solely as a result of decreased polyglutamation.
Growth inhibition was measured for inhibition of growth in CCRF-CEM sublines resistant to MTX solely as a result of decreased polyglutamation.
|
[PMID: 9554874] |
| CCRF-CEM | IC50 |
29 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against CCRF-CEM leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against CCRF-CEM leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| COLO 205 | IC50 |
3.27 μM
Compound: 6
|
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| COLO 205 | IC50 |
870 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against COLO 205 Colon cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against COLO 205 Colon cell lines (Human tumor cells )
|
[PMID: 9857098] |
| COLO 320DM | IC50 |
5.25 μM
Compound: 6
|
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| Colon 26 | IC50 |
>40 μM
Compound: MTX
|
Inhibitory concentration of compound was tested against Colon 26 Mouse Colorectal Carcinoma on 4 hour exposure
Inhibitory concentration of compound was tested against Colon 26 Mouse Colorectal Carcinoma on 4 hour exposure
|
[PMID: 8201595] |
| Colon 26 | IC50 |
31 nM
Compound: MTX
|
Inhibitory concentration of compound was tested against Colon 26 tumor growth cell line
Inhibitory concentration of compound was tested against Colon 26 tumor growth cell line
|
[PMID: 8201595] |
| DAN-G | IC50 |
0.077 μM
Compound: Methotrexate
|
Cytotoxicity against human DAN-G cells after 96 hrs by crystal violet staining
Cytotoxicity against human DAN-G cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| Daoy | IC50 |
9 nM
Compound: MTX
|
Cytotoxic activity was evaluated against Daoy tumor cells
Cytotoxic activity was evaluated against Daoy tumor cells
|
[PMID: 8632413] |
| DLD-1 | IC50 |
>60 μg/mL
Compound: methotrexate
|
Growth inhibition of human DLD1 cells after 72 hrs
Growth inhibition of human DLD1 cells after 72 hrs
|
[PMID: 17569517] |
| DU-145 | IC50 |
23 nM
Compound: MTX (1)
|
The IC50 value was measured on DU-145 cell line in prostate tumor type.
The IC50 value was measured on DU-145 cell line in prostate tumor type.
|
[PMID: 9022795] |
| DU-145 | IC50 |
45 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against DU-145 prostate cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against DU-145 prostate cell lines (Human tumor cells )
|
[PMID: 9857098] |
| Ehrlich | IC50 |
0.0126 μM
Compound: MTX
|
Concentration required for 50% inhibition against Ehrlich cells
Concentration required for 50% inhibition against Ehrlich cells
|
[PMID: 6403710] |
| EKVX | IC50 |
>1000 nM
Compound: MTX (1)
|
The IC50 value was measured on EKVX cell line in NSCL tumor type.
The IC50 value was measured on EKVX cell line in NSCL tumor type.
|
[PMID: 9022795] |
| EKVX | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against EKVX lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against EKVX lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| EL4 | IC50 |
5.1 μM
Compound: methotrexate
|
Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25951057] |
| EL4 | IC50 |
1.57 μM
Compound: MTX
|
Inhibitory growth of EL4 thymoma cell line from C57BL/6 mice
Inhibitory growth of EL4 thymoma cell line from C57BL/6 mice
|
[PMID: 9379448] |
| Epidermoid carcinoma cell line | ED50 |
0.001 μM
Compound: MTX
|
Concentration required for inhibition of colony formation (cytotoxicity) against human epidermoid carcinoma cell number 2
Concentration required for inhibition of colony formation (cytotoxicity) against human epidermoid carcinoma cell number 2
|
[PMID: 6948961] |
| FaDu | EC50 |
11.3 nM
Compound: MTX
|
Growth inhibition of human squamous cell carcinoma FaDu cells during continuous Exposure (0-12 h)
Growth inhibition of human squamous cell carcinoma FaDu cells during continuous Exposure (0-12 h)
|
[PMID: 10956221] |
| FaDu | EC50 |
17 nM
Compound: Methotrexate(MTX)
|
Growth inhibition of FaDu human head and neck squamous cell carcinoma cell lines.
Growth inhibition of FaDu human head and neck squamous cell carcinoma cell lines.
|
[PMID: 11384244] |
| FaDu | EC50 |
0.017 μM
Compound: MTX
|
Growth inhibition against Human squamous cell line(Fadu)
Growth inhibition against Human squamous cell line(Fadu)
|
[PMID: 7473577] |
| FaDu | EC50 |
0.017 μM
Compound: MTX
|
The compound was tested for Growth inhibition of the human squamous cell carcinoma FaDu cells
The compound was tested for Growth inhibition of the human squamous cell carcinoma FaDu cells
|
[PMID: 7562910] |
| FaDu | EC50 |
31 nM
Compound: MTX
|
Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound FaDu cell line
Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound FaDu cell line
|
[PMID: 7783147] |
| FaDu | EC50 |
19 nM
Compound: MTX
|
the growth inhibition of, (during continuous exposure) human squamous cell carcinoma FaDu at resistance mechanism - sensitive
the growth inhibition of, (during continuous exposure) human squamous cell carcinoma FaDu at resistance mechanism - sensitive
|
[PMID: 8164259] |
| Fibroblast | IC50 |
180 nM
Compound: MTX, methotrexate
|
Cytotoxicity against mouse wild type fibroblast cells by MTT assay
Cytotoxicity against mouse wild type fibroblast cells by MTT assay
|
[PMID: 17383876] |
| H35 | IC50 |
0.01 μM
Compound: MTX
|
Growth inhibition of H35 cell lines
Growth inhibition of H35 cell lines
|
[PMID: 6737432] |
| H35R0.3 | IC50 |
0.085 μM
Compound: MTX
|
Compound was tested for growth inhibition of H35 Hepatoma cells.
Compound was tested for growth inhibition of H35 Hepatoma cells.
|
[PMID: 1992121] |
| H35R0.3 | IC50 |
18 μM
Compound: MTX
|
Compound was tested for inhibition of folinic acid transport in H35 Hepatoma cells.
Compound was tested for inhibition of folinic acid transport in H35 Hepatoma cells.
|
[PMID: 1992121] |
| H35R0.3 | IC50 |
906 nM
Compound: MTX
|
Inhibition of growth of H35R cells
Inhibition of growth of H35R cells
|
[PMID: 2542557] |
| H35R0.3 | IC50 |
1.8 μM
Compound: MTX
|
Growth inhibition of H35R0.3 cell lines
Growth inhibition of H35R0.3 cell lines
|
[PMID: 6737432] |
| HBL-100 | IC50 |
0.04 μM
Compound: MTX
|
Anticancer activity against Homo sapiens (human) HBL100 cells after 72 hr by MTT assay
Anticancer activity against Homo sapiens (human) HBL100 cells after 72 hr by MTT assay
|
10.1007/s00044-012-0279-4 |
| HCC 2998 | IC50 |
110 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against HCC2998 Colon cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against HCC2998 Colon cell lines (Human tumor cells )
|
[PMID: 9857098] |
| HCT-116 | GI50 |
>50 μM
Compound: MTX
|
Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT)
Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT)
|
[PMID: 15267250] |
| HCT-116 | GI50 |
0.01 μM
Compound: MTX
|
Growth inhibitory activity against human HCT116 cell line
Growth inhibitory activity against human HCT116 cell line
|
[PMID: 15267250] |
| HCT-116 | GI50 |
0.015 μM
Compound: MTX
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26994844] |
| HCT-116 | IC50 |
0.75 μM
Compound: MTX
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 27886545] |
| HCT-116 | GI50 |
0.015 μM
Compound: MTX
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 28177228] |
| HCT-116 | GI50 |
0.13 μM
Compound: MTX
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| HCT-116 | IC50 |
32.7 nM
Compound: Methotrexate
|
Cytotoxicity against CD133 positive human HCT116 cells
Cytotoxicity against CD133 positive human HCT116 cells
|
[PMID: 29468872] |
| HCT-116 | IC50 |
0.13 μM
Compound: MTX
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
|
[PMID: 29691154] |
| HCT-116 | IC50 |
9.25 μM
Compound: MTX
|
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HCT-116 | IC50 |
30 nM
Compound: MTX (1)
|
The IC50 value was measured on HCT116 cell line in colon tumor type.
The IC50 value was measured on HCT116 cell line in colon tumor type.
|
[PMID: 9022795] |
| HCT-116 | IC50 |
30 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against HCT116 Colon cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against HCT116 Colon cell lines (Human tumor cells )
|
[PMID: 9857098] |
| HCT-15 | IC50 |
30 nM
Compound: MTX (1)
|
The IC50 value was measured on HCT-15 cell line in colon tumor type.
The IC50 value was measured on HCT-15 cell line in colon tumor type.
|
[PMID: 9022795] |
| HCT-15 | IC50 |
30 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against HCT-15 Colon cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against HCT-15 Colon cell lines (Human tumor cells )
|
[PMID: 9857098] |
| HEK293 | IC50 |
0.022 μM
Compound: Methotrexate
|
Cytotoxicity activity against HEK293 cells
Cytotoxicity activity against HEK293 cells
|
[PMID: 27217001] |
| HEK293 | IC50 |
28.6 nM
Compound: MTX
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HEK293 | IC50 |
35 nM
Compound: MTX
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HEK293 | IC50 |
1.27 μM
Compound: Methotrexate
|
Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
|
10.1007/s00044-012-0260-2 |
| HeLa | IC50 |
0.1 μM
Compound: MTX
|
Cytotoxicity against human HeLa cells after 48 hrs
Cytotoxicity against human HeLa cells after 48 hrs
|
[PMID: 18555562] |
| HeLa | IC50 |
0.022 μM
Compound: Methotrexate
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 27217001] |
| HeLa | IC50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 28152430] |
| HeLa | GI50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| HeLa | IC50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 29691154] |
| HeLa | IC50 |
21 nM
Compound: MTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HeLa | IC50 |
59.3 nM
Compound: MTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HeLa | IC50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTS assay
|
[PMID: 32058237] |
| HeLa | IC50 |
27.94 μM
Compound: Methotrexate
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 32503691] |
| HeLa | IC50 |
0.82 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability preincubated for 12 hrs followed by 4 Gy irradiation and measured after 60 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability preincubated for 12 hrs followed by 4 Gy irradiation and measured after 60 hrs by MTT assay
|
[PMID: 32676149] |
| HeLa | IC50 |
1.5 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 12 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 12 hrs by MTT assay
|
[PMID: 32676149] |
| HeLa | IC50 |
13.69 μM
Compound: MTX
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HEp-2 | ED50 |
0.0024 μM
Compound: MTX
|
Effective dose against H.Ep.-2 cells
Effective dose against H.Ep.-2 cells
|
[PMID: 7057425] |
| HEp-2 | ED50 |
2.4 nM
Compound: methotrexate
|
Tested for cloning suppression test against H.Ep.-2 cells
Tested for cloning suppression test against H.Ep.-2 cells
|
[PMID: 7365749] |
| HepG2 | IC50 |
0.99 μM
Compound: MTX
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25668494] |
| HepG2 | IC50 |
15.8 μM
Compound: methotrexate
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27186821] |
| HepG2 | IC50 |
0.022 μM
Compound: Methotrexate
|
Antiproliferative activity against human HepG2 cells
Antiproliferative activity against human HepG2 cells
|
[PMID: 27217001] |
| HepG2 | IC50 |
0.41 μM
Compound: MTX
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27886545] |
| HepG2 | IC50 |
0.3 μM
Compound: Methotrexate
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for overnight by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for overnight by MTT assay
|
[PMID: 31260892] |
| HepG2 | IC50 |
21.9 μM
Compound: MTX
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HL-60 | IC50 |
0.012 μM
Compound: methotrexate
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 11170674] |
| HL-60 | IC50 |
6.92 nM
Compound: methotrxate
|
Antiproliferative activity against human HL60 cells after 48 hrs by trypan blue exclusion test
Antiproliferative activity against human HL60 cells after 48 hrs by trypan blue exclusion test
|
[PMID: 17497807] |
| HL-60 | IC50 |
0.21 μM
Compound: MTX
|
Cytotoxicity against human HL60 cells after 48 hrs
Cytotoxicity against human HL60 cells after 48 hrs
|
[PMID: 18555562] |
| HL-60 | IC50 |
1.09 μM
Compound: MTX
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 27886545] |
| HL-60 | IC50 |
0.0227 μM
Compound: MTX
|
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 28152430] |
| HL-60 | GI50 |
0.038 μM
Compound: MTX
|
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| HL-60 | IC50 |
0.025 μM
Compound: MTX
|
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 29691154] |
| HL-60 | IC50 |
8.9 nM
Compound: MTX
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs in absence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HL-60 | IC50 |
9.8 nM
Compound: MTX
|
Cytotoxicity against human HL60 cells assessed reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
Cytotoxicity against human HL60 cells assessed reduction in cell viability incubated for 48 hrs in presence of ROS scavenger pyruvate by Alamar blue assay
|
[PMID: 31843461] |
| HL-60 | IC50 |
0.023 μM
Compound: MTX
|
Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 32058237] |
| HL-60 | ED50 |
<0.05 μM
Compound: MTX
|
Median-effective concentration for inhibition of human HL-60 cell growth at 48 h
Median-effective concentration for inhibition of human HL-60 cell growth at 48 h
|
[PMID: 3373490] |
| HL-60 | ED50 |
<<0.05 μM
Compound: MTX
|
Median-effective concentration for inhibition of human HL-60 cell growth at 72 h
Median-effective concentration for inhibition of human HL-60 cell growth at 72 h
|
[PMID: 3373490] |
| HL-60 | ED50 |
0.1 μM
Compound: MTX
|
Inhibition of [6-3H]-dUrd incorporation into DNA in HL-60 cells
Inhibition of [6-3H]-dUrd incorporation into DNA in HL-60 cells
|
[PMID: 3373490] |
| HL-60 | ED50 |
609 μM
Compound: MTX
|
Median-effective concentration for inhibition of human HL-60 cell growth at 24 h
Median-effective concentration for inhibition of human HL-60 cell growth at 24 h
|
[PMID: 3373490] |
| HL-60 | IC50 |
8.1 nM
Compound: MTX
|
Tested for the ability to inhibit growth in vitro against HL60
Tested for the ability to inhibit growth in vitro against HL60
|
[PMID: 8277497] |
| HL-60 | IC50 |
39 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against HL-60(TB) leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against HL-60(TB) leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| HL-60 | IC50 |
12 nM
Compound: METHOTREXATE
|
Compound was tested for its anticancer activity against HL-60 cells.
Compound was tested for its anticancer activity against HL-60 cells.
|
10.1016/S0960-894X(96)00486-6 |
| HL-60 | IC50 |
0.012 μM
Compound: Methotrexate (MTX)
|
Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells
Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells
|
10.1016/S0960-894X(97)00071-1 |
| HOP-92 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against HOP-92 lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against HOP-92 lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| Hs-578T | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against Hs 578.T breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against Hs 578.T breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| HSC-2 | CC50 |
>400 μM
Compound: MTX
|
Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay
|
[PMID: 33744685] |
| HT-29 | IC50 |
0.01 μg/mL
Compound: ametropterin
|
Antitumor activity against human HT-29 cells
Antitumor activity against human HT-29 cells
|
[PMID: 10579858] |
| HT-29 | GI50 |
>50 μM
Compound: MTX
|
Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT)
Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT)
|
[PMID: 15267250] |
| HT-29 | GI50 |
0.07 μM
Compound: MTX
|
Growth inhibitory activity against human HT-29 cell line
Growth inhibitory activity against human HT-29 cell line
|
[PMID: 15267250] |
| HT-29 | IC50 |
0.23 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 20846760] |
| HT-29 | GI50 |
0.04 μM
Compound: Methotrexate
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| HT-29 | IC50 |
1.4 μM
Compound: MTX
|
Cytostatic activity against human HT-29 cells after 4 days by MTT assay
Cytostatic activity against human HT-29 cells after 4 days by MTT assay
|
[PMID: 22480495] |
| HT-29 | GI50 |
0.04 μM
Compound: Methotrexate
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| HT-29 | IC50 |
3.45 μM
Compound: 6
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| HT-29 | IC50 |
4400 nM
Compound: Methotrexate
|
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 2778449] |
| HT-29 | GI50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| HT-29 | IC50 |
47.82 μg/mL
Compound: MTX
|
Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
|
[PMID: 30554970] |
| HT-29 | IC50 |
>100 μM
Compound: MTX
|
Antiproliferative activity against human HT29 cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human HT29 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 32058237] |
| HT-29 | IC50 |
0.018 μM
Compound: MTX
|
Inhibition of cell growth against HT-29 human gastrointestinal adenocarcinoma cell lines in vitro
Inhibition of cell growth against HT-29 human gastrointestinal adenocarcinoma cell lines in vitro
|
[PMID: 3612694] |
| HT-29 | IC50 |
0.018 μM
Compound: 1a
|
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HT-29 assay
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HT-29 assay
|
[PMID: 3968685] |
| HT-29 | IC50 |
0.018 μM
Compound: MTX
|
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HT-29
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HT-29
|
[PMID: 6694171] |
| HT-29 | IC50 |
32 nM
Compound: MTX (1)
|
The IC50 value was measured on HT-29 cell line in colon tumor type.
The IC50 value was measured on HT-29 cell line in colon tumor type.
|
[PMID: 9022795] |
| HT-29 | IC50 |
0.23 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
10.1007/s00044-013-0773-3 |
| HuTu80 | IC50 |
0.009 μM
Compound: MTX
|
Inhibition of cell growth against HuTu 80 human gastrointestinal adenocarcinoma cell lines in vitro
Inhibition of cell growth against HuTu 80 human gastrointestinal adenocarcinoma cell lines in vitro
|
[PMID: 3612694] |
| HuTu80 | EC50 |
4.5 nM
Compound: MTX
|
Inhibition of growth (cytotoxicity) of HuTu 80 cell line in vitro
Inhibition of growth (cytotoxicity) of HuTu 80 cell line in vitro
|
[PMID: 6410066] |
| HUVEC | IC50 |
6.13 μM
Compound: MTX
|
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31200235] |
| IGROV-1 | IC50 |
21 nM
Compound: methotrexate
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
22 nM
Compound: methotrexate
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
21 nM
Compound: MTX
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| IGROV-1 | IC50 |
22 nM
Compound: MTX
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| IGROV-1 | IC50 |
65 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against IGROV1 Ovary cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against IGROV1 Ovary cell lines (Human tumor cells )
|
[PMID: 9857098] |
| Jurkat | GI50 |
1.25 μM
Compound: Methotrexate
|
Growth inhibition of human Jurkat cells after 72 hrs by MTT assay
Growth inhibition of human Jurkat cells after 72 hrs by MTT assay
|
[PMID: 21802949] |
| K562 | IC50 |
419 μM
Compound: 1
|
In vitro cytotoxic concentration measured against human myelogenous leukemia K562 cells
In vitro cytotoxic concentration measured against human myelogenous leukemia K562 cells
|
[PMID: 15780632] |
| K562 | GI50 |
0.03 μM
Compound: Methotrexate
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| K562 | IC50 |
26 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against K562 leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against K562 leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| KB | IC50 |
20 nM
Compound: methotrexate
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
|
[PMID: 18680275] |
| KB | IC50 |
6 nM
Compound: methotrexate
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
|
[PMID: 18680275] |
| KB | IC50 |
20 nM
Compound: MTX
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| KB | IC50 |
6 nM
Compound: MTX
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| KB | IC50 |
8.5 nM
Compound: MTX
|
Inhibition of colony formation of human KB cells endogenously expressing RFC/FRalpha/PCFT incubated for 14 days by methylene blue staining based clonogenicty assay
Inhibition of colony formation of human KB cells endogenously expressing RFC/FRalpha/PCFT incubated for 14 days by methylene blue staining based clonogenicty assay
|
[PMID: 22243528] |
| KB | IC50 |
20.9 μM
Compound: MTX
|
Antiproliferative activity against human KB cells after 48 hrs
Antiproliferative activity against human KB cells after 48 hrs
|
[PMID: 23124219] |
| KB | IC50 |
20 nM
Compound: MTX
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
|
[PMID: 24111942] |
| KB | IC50 |
6 nM
Compound: MTX
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| KB | IC50 |
20 nM
Compound: MTX
|
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| KB | IC50 |
6 nM
Compound: MTX
|
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| KB | IC50 |
0.01 μM
Compound: MTX
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25668494] |
| KB | IC50 |
0.01 μM
Compound: MTX
|
Antiproliferative activity against human KB cells after 72 hrs by MTT assay in presence of leucovorin
Antiproliferative activity against human KB cells after 72 hrs by MTT assay in presence of leucovorin
|
[PMID: 27017552] |
| KB | IC50 |
20 nM
Compound: MTX
|
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay
|
[PMID: 29425443] |
| KB | IC50 |
6 nM
Compound: MTX
|
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
|
[PMID: 29425443] |
| KB | IC50 |
10 nM
Compound: MTX
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31200235] |
| KB | IC50 |
20 nM
Compound: MTX
|
Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of folic acid by Cell-Titer Blue assay
Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of folic acid by Cell-Titer Blue assay
|
[PMID: 32503687] |
| KB | IC50 |
6 nM
Compound: MTX
|
Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
|
[PMID: 32503687] |
| KB | ED50 |
0.004 μg/mL
Compound: 1, MTX
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 448685] |
| KB | IC50 |
19 nM
Compound: MTX
|
Inhibitory concentration of compound was tested against KB tumor growth cell line
Inhibitory concentration of compound was tested against KB tumor growth cell line
|
[PMID: 8201595] |
| KM12 | IC50 |
42 nM
Compound: MTX (1)
|
The IC50 value was measured on KM-12 cell line in colon tumor type.
The IC50 value was measured on KM-12 cell line in colon tumor type.
|
[PMID: 9022795] |
| KM12 | IC50 |
33 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against KM-12 Colon cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against KM-12 Colon cell lines (Human tumor cells )
|
[PMID: 9857098] |
| L1210 | IC50 |
0.0034 μM
Compound: MTX
|
In vitro inhibition of L1210 cell growth
In vitro inhibition of L1210 cell growth
|
[PMID: 1501226] |
| L1210 | IC50 |
3.9 nM
Compound: Methotrexate
|
Concentration required to inhibit 50% growth of L1210 cells in culture.
Concentration required to inhibit 50% growth of L1210 cells in culture.
|
[PMID: 1732549] |
| L1210 | IC50 |
4.51 nM
Compound: MTX
|
Inhibitory concentration was evaluated as the concentration required for inhibition of L1210 cells.
Inhibitory concentration was evaluated as the concentration required for inhibition of L1210 cells.
|
[PMID: 1732551] |
| L1210 | IC50 |
0.0046 μM
Compound: 1
|
Ability to inhibit L1210 murine leukemia tumor cell growth in culture after 48 hr of its exposure.
Ability to inhibit L1210 murine leukemia tumor cell growth in culture after 48 hr of its exposure.
|
[PMID: 1992118] |
| L1210 | IC50 |
200 μM
Compound: 1
|
Ability to inhibit MTX-resistant L1210/R81 tumor cell growth was determined.
Ability to inhibit MTX-resistant L1210/R81 tumor cell growth was determined.
|
[PMID: 1992118] |
| L1210 | IC50 |
0.009 μM
Compound: Methotrexate
|
Compound was evaluated for cell growth inhibition of murine (L1210) leukemic cells
Compound was evaluated for cell growth inhibition of murine (L1210) leukemic cells
|
[PMID: 1992122] |
| L1210 | IC50 |
4.6 nM
Compound: methotrexate(MTX)
|
Compound was evaluated for the growth inhibition of L1210 cells
Compound was evaluated for the growth inhibition of L1210 cells
|
[PMID: 1995880] |
| L1210 | IC50 |
5 nM
Compound: Methotrexate (MTX)
|
Concentration inhibiting L1210 cell growth in culture
Concentration inhibiting L1210 cell growth in culture
|
[PMID: 2296020] |
| L1210 | IC50 |
3.92 nM
Compound: MTX
|
Inhibitory activity for the growth inhibition of L1210 cell line.
Inhibitory activity for the growth inhibition of L1210 cell line.
|
[PMID: 2299633] |
| L1210 | IC50 |
2.55 nM
Compound: MTX
|
Compound was evaluated for inhibitory effect on growth of L1210 cells at IC50 (n=4)
Compound was evaluated for inhibitory effect on growth of L1210 cells at IC50 (n=4)
|
[PMID: 2423690] |
| L1210 | IC50 |
0.035 μM
Compound: MTX
|
Compound was tested for its ability to inhibit dihydrofolate reductase purified from murine L1210 cells
Compound was tested for its ability to inhibit dihydrofolate reductase purified from murine L1210 cells
|
[PMID: 2428979] |
| L1210 | IC50 |
0.2 μM
Compound: MTX
|
Compound was tested for its ability to inhibit L1210 cell growth
Compound was tested for its ability to inhibit L1210 cell growth
|
[PMID: 2428979] |
| L1210 | IC50 |
0.0044 μM
Compound: MTX
|
Inhibition of the growth of methotrexate sensitive L1210 leukemia/S cells in culture
Inhibition of the growth of methotrexate sensitive L1210 leukemia/S cells in culture
|
[PMID: 2704031] |
| L1210 | IC50 |
186 μM
Compound: MTX
|
Inhibition of the growth of methotrexate resistant L1210 leukemia/R 81 cells in culture
Inhibition of the growth of methotrexate resistant L1210 leukemia/R 81 cells in culture
|
[PMID: 2704031] |
| L1210 | IC50 |
0.002 μM
Compound: MTX
|
Compound was tested for its ability to inhibit growth of L1210 mouse leukemia cells
Compound was tested for its ability to inhibit growth of L1210 mouse leukemia cells
|
[PMID: 2871191] |
| L1210 | IC50 |
0.0046 μM
Compound: 1 (MTX)
|
Tested for cell-growth inhibition against mouse leukemic L1210 cells
Tested for cell-growth inhibition against mouse leukemic L1210 cells
|
[PMID: 2898531] |
| L1210 | IC50 |
0.025 μM
Compound: 1 (MTX)
|
Tested for inhibition against purified Dihydrofolate reductase from L1210 murine leukemia cells
Tested for inhibition against purified Dihydrofolate reductase from L1210 murine leukemia cells
|
[PMID: 2898531] |
| L1210 | IC50 |
0.009 μM
Compound: 1 (MTX)
|
Inhibition of cell growth against L1210 murine leukemia cells
Inhibition of cell growth against L1210 murine leukemia cells
|
[PMID: 2918496] |
| L1210 | IC50 |
6.0 x 10-5 M
Compound: MTX
|
Inhibition of thymidylate synthesis in permeabilised cells
Inhibition of thymidylate synthesis in permeabilised cells
|
[PMID: 3091832] |
| L1210 | IC50 |
2.5 x 10-9 M
Compound: MTX
|
Compound was evaluated for growth inhibition in L1210 murine leukemia cells
Compound was evaluated for growth inhibition in L1210 murine leukemia cells
|
[PMID: 3091834] |
| L1210 | IC50 |
0.005 nM
Compound: Methotrexate
|
Inhibition of L1210 cultured murine leukemia cell growth
Inhibition of L1210 cultured murine leukemia cell growth
|
[PMID: 3112397] |
| L1210 | IC50 |
200 nM
Compound: Methotrexate
|
Inhibition of L1210/R81 murine leukemia cell growth
Inhibition of L1210/R81 murine leukemia cell growth
|
[PMID: 3112397] |
| L1210 | IC50 |
3.9 x 10-9 M
Compound: MTX
|
Tested for growth inhibition of L1210 leukemia cells
Tested for growth inhibition of L1210 leukemia cells
|
[PMID: 3121855] |
| L1210 | IC50 |
>2.0 x 10-5 M
Compound: MTX
|
Inhibition of GAR transformylase from mammalian L1210 cells
Inhibition of GAR transformylase from mammalian L1210 cells
|
[PMID: 3184124] |
| L1210 | IC50 |
2.1 nM
Compound: MTX
|
Evaluated for cell growth inhibition of L1210 cells in cultures
Evaluated for cell growth inhibition of L1210 cells in cultures
|
[PMID: 3184124] |
| L1210 | IC50 |
20 μM
Compound: MTX
|
Inhibitory activity against thymidylate synthase isolated from L1210 leukemia cells
Inhibitory activity against thymidylate synthase isolated from L1210 leukemia cells
|
[PMID: 3339615] |
| L1210 | IC50 |
0.005 μM
Compound: MTX
|
Inhibitory activity against cultured L1210 cells
Inhibitory activity against cultured L1210 cells
|
[PMID: 3351853] |
| L1210 | IC50 |
0.0045 μM
Compound: MTX
|
Inhibition of cell growth of murine L-1210 cells
Inhibition of cell growth of murine L-1210 cells
|
[PMID: 3373490] |
| L1210 | IC50 |
0.0046 μM
Compound: MTX
|
Inhibitory concentration against growth of L1210 cell line
Inhibitory concentration against growth of L1210 cell line
|
[PMID: 3385730] |
| L1210 | IC50 |
0.002 μM
Compound: MTX
|
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells.
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells.
|
[PMID: 3462394] |
| L1210 | IC50 |
0.02 μM
Compound: MTX
|
Compound was tested for its inhibitory concentration to inhibit the enzyme Dihydro Folate Reductase (DHFR) from murine L1210 leukemia cells.
Compound was tested for its inhibitory concentration to inhibit the enzyme Dihydro Folate Reductase (DHFR) from murine L1210 leukemia cells.
|
[PMID: 3462394] |
| L1210 | IC50 |
0.03 μM
Compound: MTX
|
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells; Range=0.01 to 0.03
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells; Range=0.01 to 0.03
|
[PMID: 3462394] |
| L1210 | IC50 |
220 μM
Compound: MTX
|
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells and a subline (L1210 / R81).
Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells and a subline (L1210 / R81).
|
[PMID: 3462394] |
| L1210 | IC50 |
0.002 μM
Compound: MTX
|
Cell growth inhibition against mouse leukemia L1210 cells
Cell growth inhibition against mouse leukemia L1210 cells
|
[PMID: 3872941] |
| L1210 | IC50 |
19 μM
Compound: MTX
|
Cell growth inhibition against mouse leukemia L1210/R71 cells
Cell growth inhibition against mouse leukemia L1210/R71 cells
|
[PMID: 3872941] |
| L1210 | IC50 |
220 μM
Compound: MTX
|
Cell growth inhibition against mouse leukemia L1210/R81 cells
Cell growth inhibition against mouse leukemia L1210/R81 cells
|
[PMID: 3872941] |
| L1210 | IC50 |
0.012 μM
Compound: 1a
|
Evaluated for the growth inhibition of L1210 /S cells
Evaluated for the growth inhibition of L1210 /S cells
|
[PMID: 3968685] |
| L1210 | IC50 |
0.045 μM
Compound: 1a
|
Evaluated for the inhibition of dihydrofolate reductase from L1210 mouse leukemia cells
Evaluated for the inhibition of dihydrofolate reductase from L1210 mouse leukemia cells
|
[PMID: 3968685] |
| L1210 | IC50 |
1 μM
Compound: 1a
|
Evaluated for the uptake of Methotrexate in L1210 leukemia cells
Evaluated for the uptake of Methotrexate in L1210 leukemia cells
|
[PMID: 3968685] |
| L1210 | IC50 |
1.0 x 10-8 M
Compound: MTX
|
Inhibitory concentration against the growth of L1210 murine leukemia cells in tissue culture.
Inhibitory concentration against the growth of L1210 murine leukemia cells in tissue culture.
|
[PMID: 4009615] |
| L1210 | IC50 |
3.28 nM
Compound: MTX
|
Antitumor activity against L1210 cell in mice
Antitumor activity against L1210 cell in mice
|
[PMID: 4020824] |
| L1210 | IC50 |
0.00084 μM
Compound: MTX
|
Concentration required for 50% inhibition against L1210 cells
Concentration required for 50% inhibition against L1210 cells
|
[PMID: 6403710] |
| L1210 | IC50 |
0.84 nM
Compound: MTX
|
Concentration required for 50% inhibition against L1210 cells
Concentration required for 50% inhibition against L1210 cells
|
[PMID: 6403710] |
| L1210 | EC50 |
3.2 nM
Compound: MTX
|
Inhibition of growth (cytotoxicity) of L1210 cell line in vitro
Inhibition of growth (cytotoxicity) of L1210 cell line in vitro
|
[PMID: 6410066] |
| L1210 | IC50 |
0.024 μM
Compound: MTX
|
Growth inhibition of L1210 cell lines
Growth inhibition of L1210 cell lines
|
[PMID: 6737432] |
| L1210 | IC50 |
50 nM
Compound: MTX
|
Inhibitory activity towards dihydrofolate reductase in L1210 murine leukemia cell lines
Inhibitory activity towards dihydrofolate reductase in L1210 murine leukemia cell lines
|
[PMID: 6737432] |
| L1210 | IC50 |
2.7 x 10-9 M
Compound: 4 (Methotrexate)
|
Inhibitory concentration of compound in growth of L-1210 cells
Inhibitory concentration of compound in growth of L-1210 cells
|
[PMID: 6793726] |
| L1210 | ED50 |
0.016 μM
Compound: methotrexate
|
Cytotoxic activity against the L1210 cell cultures
Cytotoxic activity against the L1210 cell cultures
|
[PMID: 6928967] |
| L1210 | IC50 |
2.7 nM
Compound: MTX
|
In vitro inhibition of L1210 cell growth in rodent neoplastic cells
In vitro inhibition of L1210 cell growth in rodent neoplastic cells
|
[PMID: 7108907] |
| L1210 | IC50 |
9 nM
Compound: MTX
|
Tested for the ability to inhibit growth in vitro against L1210
Tested for the ability to inhibit growth in vitro against L1210
|
[PMID: 8277497] |
| L1210 | IC50 |
9.5 nM
Compound: MTX
|
Inhibition of growth in L1210 murine leukemia cells in culture expressed as IC50 (nM)
Inhibition of growth in L1210 murine leukemia cells in culture expressed as IC50 (nM)
|
[PMID: 8340923] |
| L1210 | IC50 |
0.007 μM
Compound: MTX (Methotrexate)
|
Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(In this study)
Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(In this study)
|
[PMID: 8863812] |
| L1210 | IC50 |
0.073 μM
Compound: MTX (Methotrexate)
|
compound was evaluated for the inhibitory activity against Dihydrofolate reductase in permeabilised L1210 cells.
compound was evaluated for the inhibitory activity against Dihydrofolate reductase in permeabilised L1210 cells.
|
[PMID: 8863812] |
| L1210 | IC50 |
1.3 μM
Compound: MTX (Methotrexate)
|
Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(From ref 12b)
Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(From ref 12b)
|
[PMID: 8863812] |
| L1210 | IC50 |
20 nM
Compound: MTX (Methotrexate)
|
Concentration required to inhibit the growth of L1210 cells
Concentration required to inhibit the growth of L1210 cells
|
[PMID: 9022804] |
| L1210 | IC50 |
20 nM
Compound: MTX
|
Concentration required to inhibit the growth of L1210 cells.
Concentration required to inhibit the growth of L1210 cells.
|
[PMID: 9022805] |
| L1210 (R81) | IC50 |
0.035 μM
Compound: MTX
|
Compound was tested for its ability to inhibit purified dihydrofolate reductase(DHFR) from L1210/R81 cells
Compound was tested for its ability to inhibit purified dihydrofolate reductase(DHFR) from L1210/R81 cells
|
[PMID: 2871191] |
| L1210 (R81) | IC50 |
220 μM
Compound: MTX
|
Compound was tested for its ability to inhibit growth of L1210/R81 cells
Compound was tested for its ability to inhibit growth of L1210/R81 cells
|
[PMID: 2871191] |
| L1210 (R81) | IC50 |
197 μM
Compound: 1 (MTX)
|
Tested for cell-growth inhibition against mouse leukemic L1210/R81 cells
Tested for cell-growth inhibition against mouse leukemic L1210/R81 cells
|
[PMID: 2898531] |
| L1210 (R81) | IC50 |
25 nM
Compound: Methotrexate
|
Inhibition of dihydrofolate reductase(DHFR) from L1210/R81 cells
Inhibition of dihydrofolate reductase(DHFR) from L1210/R81 cells
|
[PMID: 3112397] |
| L1210 (R81) | IC50 |
200 μM
Compound: MTX
|
Inhibitory concentration against growth of L1210/R81 cell line
Inhibitory concentration against growth of L1210/R81 cell line
|
[PMID: 3385730] |
| L1210 (R81) | IC50 |
205 μM
Compound: 1a
|
Evaluated for 50% inhibition of growth of L1210 / R81 cells (48 h), relative to untreated controls
Evaluated for 50% inhibition of growth of L1210 / R81 cells (48 h), relative to untreated controls
|
[PMID: 3968685] |
| LCLC-103H cell line | IC50 |
0.025 μM
Compound: Methotrexate
|
Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining
Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| LNCaP | IC50 |
0.3 μM
Compound: MTX
|
Cytostatic activity against human LNCAP cells after 4 days by MTT assay
Cytostatic activity against human LNCAP cells after 4 days by MTT assay
|
[PMID: 22480495] |
| LOX IMVI | IC50 |
0.057 μg/mL
Compound: methotrexate
|
Growth inhibition of human LOX IMVI cells after 72 hrs
Growth inhibition of human LOX IMVI cells after 72 hrs
|
[PMID: 17569517] |
| LOX IMVI | IC50 |
26 nM
Compound: MTX (1)
|
The IC50 value was measured on LOX IMVI cell line in melanoma tumor ty
The IC50 value was measured on LOX IMVI cell line in melanoma tumor ty
|
[PMID: 9022795] |
| LOX IMVI | IC50 |
26 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against LOXIMV1 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against LOXIMV1 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| M14 | IC50 |
32 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against M14 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against M14 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| M21 | IC50 |
108 μg/mL
Compound: MTX
|
Concentration (20 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
Concentration (20 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
109 μg/mL
Compound: MTX
|
Concentration (10 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
Concentration (10 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
109 μg/mL
Compound: MTX
|
Concentration (15 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
Concentration (15 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
112 μg/mL
Compound: MTX
|
Concentration (10 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
Concentration (10 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
112 μg/mL
Compound: MTX
|
Concentration (20 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (20 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
115 μg/mL
Compound: MTX
|
Concentration (10 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (10 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
115 μg/mL
Compound: MTX
|
Concentration (20 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (20 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
117 μg/mL
Compound: MTX
|
Concentration (15 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
Concentration (15 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
118 μg/mL
Compound: MTX
|
Concentration (15 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (15 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
119 μg/mL
Compound: MTX
|
Concentration (20 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
Concentration (20 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
120 μg/mL
Compound: MTX
|
Concentration (10 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (10 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| M21 | IC50 |
121 μg/mL
Compound: MTX
|
Concentration (15 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
Concentration (15 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells
|
[PMID: 2810330] |
| Malme-3M | IC50 |
>1000 nM
Compound: MTX (1)
|
The IC50 value was measured on MALME-3M cell line in melanoma tumor type
The IC50 value was measured on MALME-3M cell line in melanoma tumor type
|
[PMID: 9022795] |
| Malme-3M | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against MALME-3M Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against MALME-3M Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| MC-38 | IC50 |
66 nM
Compound: MTX
|
Inhibitory concentration of compound was tested against Colon 38 tumor growth cell line
Inhibitory concentration of compound was tested against Colon 38 tumor growth cell line
|
[PMID: 8201595] |
| MCF7 | IC50 |
0.05 μM
Compound: Methotrexate
|
Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining
Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| MCF7 | EC50 |
0.9 μM
Compound: Methotrexate
|
Cytotoxicity against human MCF7 cells assessed as cell viability by XTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability by XTT assay
|
[PMID: 20674353] |
| MCF7 | GI50 |
0.06 μM
Compound: Methotrexate
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| MCF7 | GI50 |
0.06 μM
Compound: Methotrexate
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| MCF7 | GI50 |
0.024 μM
Compound: MTX
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 26994844] |
| MCF7 | IC50 |
0.8 μM
Compound: MTX; Methotrexate
|
Cytostatic activity against human MCF7 cells preincubated for 3 hrs followed by serum treatment for 72 hrs measured on day 4 by MTT assay
Cytostatic activity against human MCF7 cells preincubated for 3 hrs followed by serum treatment for 72 hrs measured on day 4 by MTT assay
|
[PMID: 27031212] |
| MCF7 | GI50 |
0.024 μM
Compound: MTX
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 28177228] |
| MCF7 | IC50 |
0.097 μM
Compound: MTX
|
Antiproliferative activity against human MCF7 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay
Antiproliferative activity against human MCF7 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay
|
[PMID: 28830032] |
| MCF7 | IC50 |
31.48 μg/mL
Compound: MTX
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 30554970] |
| MCF7 | IC50 |
27.09 μM
Compound: Methotrexate
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31404864] |
| MCF7 | IC50 |
49.22 μM
Compound: Methotrexate
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 32503691] |
| MCF7 | IC50 |
>22 μM
Compound: MTX
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
|
[PMID: 33479665] |
| MCF7 | IC50 |
0.015 μM
Compound: MTX
|
Antineoplastic activity against human MCF7 cells incubated for 72 hrs by prestoblue reduction assay
Antineoplastic activity against human MCF7 cells incubated for 72 hrs by prestoblue reduction assay
|
[PMID: 33479665] |
| MCF7 | IC50 |
25.32 μM
Compound: MTX
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| MCF7 | IC50 |
36 nM
Compound: MTX (1)
|
The IC50 value was measured on MCF-7 cell line in breast tumor type
The IC50 value was measured on MCF-7 cell line in breast tumor type
|
[PMID: 9022795] |
| MCF7 | IC50 |
36 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against MCF-7 breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against MCF-7 breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| MCF7 | IC50 |
2.26 μM
Compound: Methotrexate
|
Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
|
10.1007/s00044-012-0260-2 |
| MDA-MB-231 | EC50 |
80 μM
Compound: Methotrexate
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability by XTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability by XTT assay
|
[PMID: 20674353] |
| MDA-MB-231 | IC50 |
0.5 μM
Compound: 3; MTX
|
Cytotoxicity against human MDA-MB-231 cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
Cytotoxicity against human MDA-MB-231 cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
|
[PMID: 26985967] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: MTX; Methotrexate
|
Cytostatic activity against human MDA-MB-231 cells preincubated for 3 hrs followed by serum treatment for 72 hrs measured on day 4 by MTT assay
Cytostatic activity against human MDA-MB-231 cells preincubated for 3 hrs followed by serum treatment for 72 hrs measured on day 4 by MTT assay
|
[PMID: 27031212] |
| MDA-MB-231 | IC50 |
9.49 μM
Compound: MTX
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 27886545] |
| MDA-MB-435 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against MDA-MB-435 breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against MDA-MB-435 breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| MDA-MB-468 | IC50 |
0.2 μM
Compound: 3; MTX
|
Cytotoxicity against human MDA-MB-468 cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
Cytotoxicity against human MDA-MB-468 cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
|
[PMID: 26985967] |
| MEF | IC50 |
120 nM
Compound: MTX, methotrexate
|
Cytotoxicity against FKBP deficient MEF cells by MTT assay
Cytotoxicity against FKBP deficient MEF cells by MTT assay
|
[PMID: 17383876] |
| MOLT-4 | IC50 |
1.4 μM
Compound: MTX
|
Compound was evaluated for inhibition of MTX influx into MOLT-4 cells
Compound was evaluated for inhibition of MTX influx into MOLT-4 cells
|
[PMID: 1895294] |
| MOLT-4 | IC50 |
28 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against MOLT-4 leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against MOLT-4 leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| MOLT-4 | IC50 |
48 nM
Compound: METHOTREXATE
|
Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.
Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.
|
10.1016/S0960-894X(96)00486-6 |
| NCI/ADR-RES | IC50 |
78 nM
Compound: MTX (1)
|
The IC50 value was measured on MCF7-ADR cell line in breast tumor type.
The IC50 value was measured on MCF7-ADR cell line in breast tumor type.
|
[PMID: 9022795] |
| NCI/ADR-RES | IC50 |
78 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against NCI/ADR-RES breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against NCI/ADR-RES breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| NCI-H1299 | IC50 |
0.072 μM
Compound: MTX
|
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by MTS assay
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by MTS assay
|
[PMID: 28152430] |
| NCI-H1299 | GI50 |
0.072 μM
Compound: MTX
|
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by MTS assay
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by MTS assay
|
[PMID: 28711701] |
| NCI-H1299 | IC50 |
0.072 μM
Compound: MTX
|
Antiproliferative activity against human H1299 cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human H1299 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 32058237] |
| NCI-H226 | GI50 |
10.25 μM
Compound: Methotrexate
|
Growth inhibition of human NCI-H226 cells after 72 hrs by MTT assay
Growth inhibition of human NCI-H226 cells after 72 hrs by MTT assay
|
[PMID: 21802949] |
| NCI-H226 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against NCI-H226 lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against NCI-H226 lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| NCI-H23 | IC50 |
0.29 μg/mL
Compound: methotrexate
|
Growth inhibition of human NCI-H23 cells after 72 hrs
Growth inhibition of human NCI-H23 cells after 72 hrs
|
[PMID: 17569517] |
| NCI-H23 | IC50 |
43 nM
Compound: MTX (1)
|
The IC50 value was measured on NCl-H23 cell line in NSCL tumor type.
The IC50 value was measured on NCl-H23 cell line in NSCL tumor type.
|
[PMID: 9022795] |
| NCI-H23 | IC50 |
43 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against NCI-H23 lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against NCI-H23 lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| NCI-H460 | IC50 |
9.5 nM
Compound: MTX
|
Cytotoxic Activity was evaluated against H460 tumor cells
Cytotoxic Activity was evaluated against H460 tumor cells
|
[PMID: 8632413] |
| NCI-H460 | IC50 |
28 nM
Compound: MTX (1)
|
The IC50 value was measured on NCl-H460 cell line in NSCL tumor type
The IC50 value was measured on NCl-H460 cell line in NSCL tumor type
|
[PMID: 9022795] |
| NCI-H460 | IC50 |
28 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against NCI-H460 lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against NCI-H460 lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| NCI-H522 | IC50 |
229 nM
Compound: MTX (1)
|
The IC50 value was measured on NCl-H522 cell line in NSCL tumor type.
The IC50 value was measured on NCl-H522 cell line in NSCL tumor type.
|
[PMID: 9022795] |
| NCI-H522 | IC50 |
450 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against NCI-H522 lung cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against NCI-H522 lung cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| NIH3T3 | IC50 |
0.24 μg/mL
Compound: Methotrexate
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by MTT assay
|
10.1007/s00044-013-0773-3 |
| OVCAR-3 | IC50 |
398 nM
Compound: MTX (1)
|
The IC50 value was measured on OVCAR-3 cell line in ovarian tumor t
The IC50 value was measured on OVCAR-3 cell line in ovarian tumor t
|
[PMID: 9022795] |
| OVCAR-3 | IC50 |
400 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against OVCAR-3 Ovary cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against OVCAR-3 Ovary cell lines (Human tumor cells )
|
[PMID: 9857098] |
| OVCAR-4 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against OVCAR-4 Ovary cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against OVCAR-4 Ovary cell lines (Human tumor cells )
|
[PMID: 9857098] |
| OVCAR-5 | IC50 |
>1000 nM
Compound: MTX (1)
|
The IC50 value was measured on OVCAR-5 cell line in ovarian tumor type.
The IC50 value was measured on OVCAR-5 cell line in ovarian tumor type.
|
[PMID: 9022795] |
| OVCAR-5 | IC50 |
980 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against OVCAR-5 Ovary cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against OVCAR-5 Ovary cell lines (Human tumor cells )
|
[PMID: 9857098] |
| OVCAR-8 | IC50 |
31 nM
Compound: MTX (1)
|
The IC50 value was measured on OVCAR-8 cell line in ovarian tumor type.
The IC50 value was measured on OVCAR-8 cell line in ovarian tumor type.
|
[PMID: 9022795] |
| OVCAR-8 | IC50 |
31 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against OVCAR-8 Ovary cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against OVCAR-8 Ovary cell lines (Human tumor cells )
|
[PMID: 9857098] |
| P388 | IC50 |
0.002 μg/mL
Compound: ametropterin
|
Antitumor activity against mouse P388 cells
Antitumor activity against mouse P388 cells
|
[PMID: 10579858] |
| P388 | IC50 |
66 nM
Compound: Methotrexate
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 2778449] |
| P388 | IC50 |
223 nM
Compound: MTX
|
Inhibitory concentration of compound was tested against P388:Methotrexate resistant cells tumor growth cell line
Inhibitory concentration of compound was tested against P388:Methotrexate resistant cells tumor growth cell line
|
[PMID: 8201595] |
| P388 | IC50 |
23 nM
Compound: MTX
|
Inhibitory concentration of compound was tested against P388 tumor growth cell line
Inhibitory concentration of compound was tested against P388 tumor growth cell line
|
[PMID: 8201595] |
| P388 | IC50 |
6.6 nM
Compound: MTX
|
Compound was tested for the inhibition of dihydrofolate reductase in P388 cells
Compound was tested for the inhibition of dihydrofolate reductase in P388 cells
|
[PMID: 8201595] |
| P388 | IC50 |
4.8 nM
Compound: MTX
|
Cytotoxic activity was evaluated against P388D1 tumor cells
Cytotoxic activity was evaluated against P388D1 tumor cells
|
[PMID: 8632413] |
| PC-3 | IC50 |
0.027 μg/mL
Compound: methotrexate
|
Growth inhibition of human PC3 cells after 72 hrs
Growth inhibition of human PC3 cells after 72 hrs
|
[PMID: 17569517] |
| PC-3 | IC50 |
1 nM
Compound: MTX
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 20580561] |
| PC-3 | GI50 |
0.1 μM
Compound: Methotrexate
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| PC-3 | IC50 |
28.78 μM
Compound: MTX
|
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| PC-3 | IC50 |
2 nM
Compound: MTX (1)
|
The IC50 value was measured on PC-3 cell line in prostate tumor type.
The IC50 value was measured on PC-3 cell line in prostate tumor type.
|
[PMID: 9022795] |
| PC-3 | IC50 |
27 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against PC-3 prostate cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against PC-3 prostate cell lines (Human tumor cells )
|
[PMID: 9857098] |
| PPC-1 | IC50 |
0.01 μM
Compound: 1a, MTX
|
Antiproliferative activity against PPC1 cells after 72 hrs in folate depleted media
Antiproliferative activity against PPC1 cells after 72 hrs in folate depleted media
|
[PMID: 17127067] |
| PPC-1 | IC50 |
0.1 μM
Compound: 1a, MTX
|
Antiproliferative activity against PPC1 cells after 72 hrs by MTT assay
Antiproliferative activity against PPC1 cells after 72 hrs by MTT assay
|
[PMID: 17127067] |
| R1 | EC50 |
1050 nM
Compound: MTX
|
Inhibition of growth of R1 (n=2)
Inhibition of growth of R1 (n=2)
|
[PMID: 11960504] |
| R1 | EC50 |
720 nM
Compound: MTX
|
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R1 at resistance mechanism - increased DHFR
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R1 at resistance mechanism - increased DHFR
|
[PMID: 8164259] |
| R1-CCRF-CEM | EC50 |
985 nM
Compound: Methotrexate
|
Growth inhibition of MTX-resistant subline R1-CCRF-CEM Human Leukemia Cell was determined
Growth inhibition of MTX-resistant subline R1-CCRF-CEM Human Leukemia Cell was determined
|
[PMID: 12570380] |
| R1-CCRF-CEM | EC50 |
565 nM
Compound: MTX
|
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R1 cells
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R1 cells
|
[PMID: 16451071] |
| R2 | EC50 |
2600 nM
Compound: MTX
|
Inhibition of growth of R2 (n=2)
Inhibition of growth of R2 (n=2)
|
[PMID: 11960504] |
| R2 | EC50 |
2100 nM
Compound: MTX
|
Growth inhibition of MTX-resistant human CCRF-CEM R2 cells
Growth inhibition of MTX-resistant human CCRF-CEM R2 cells
|
[PMID: 15615522] |
| R2 | IC50 |
216 nM
Compound: methotrexate
|
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
|
[PMID: 18680275] |
| R2 | IC50 |
121 nM
Compound: MTX
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
216 nM
Compound: MTX
|
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
121 nM
Compound: MTX
|
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| R2 | IC50 |
120.5 nM
Compound: MTX
|
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
|
[PMID: 24256410] |
| R2 | IC50 |
216 nM
Compound: MTX
|
Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| R2 | IC50 |
>1000 nM
Compound: MTX
|
Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| R2 | IC50 |
114 nM
Compound: MTX
|
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
|
[PMID: 27458733] |
| R2 | IC50 |
114 nM
Compound: MTX
|
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
|
[PMID: 29425443] |
| R2 | IC50 |
121 nM
Compound: MTX
|
Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4 R2 cells expressing human PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4 R2 cells expressing human PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
|
[PMID: 32503687] |
| R2 | IC50 |
216 nM
Compound: MTX
|
Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4/FRalpha-null R2 cells assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4/FRalpha-null R2 cells assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay
|
[PMID: 32503687] |
| R2-CCRF-CEM | EC50 |
2630 nM
Compound: Methotrexate
|
Growth inhibition of MTX-resistant subline R2-CCRF-CEM Human Leukemia Cell was determined
Growth inhibition of MTX-resistant subline R2-CCRF-CEM Human Leukemia Cell was determined
|
[PMID: 12570380] |
| R2-CCRF-CEM | EC50 |
1700 nM
Compound: MTX
|
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R2 cells
Inhibition of growth in MTX-resistant CCRF-CEM cell line, R2 cells
|
[PMID: 16451071] |
| R30dm-CCRF-CEM | EC50 |
12.8 nM
Compound: Methotrexate
|
Growth inhibition of MTX-resistant subline R30dm-CCRF-CEM Human Leukemia Cell was determined
Growth inhibition of MTX-resistant subline R30dm-CCRF-CEM Human Leukemia Cell was determined
|
[PMID: 12570380] |
| R30dm-CCRF-CEM | EC50 |
18 nM
Compound: MTX
|
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R30dm at resistance mechanism - decreased FPGS
the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R30dm at resistance mechanism - decreased FPGS
|
[PMID: 8164259] |
| Raji | IC50 |
0.04 μM
Compound: methotrexate
|
Cytotoxicity against human Raji cells after 96 hrs by MTT assay
Cytotoxicity against human Raji cells after 96 hrs by MTT assay
|
[PMID: 18513976] |
| RAW264.7 | IC50 |
159.2 μM
Compound: Methotrexate
|
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by WST-1 assay
|
[PMID: 31260892] |
| RAW264.7 | IC50 |
5.02 μM
Compound: Methotrexate
|
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO overproduction preincubated for 1 hr prior to Escherichia coli LPS stimulation followed by further incubation for 24 hrs by Griess reagent based spectrophotome
|
[PMID: 31260892] |
| RAW264.7 | IC50 |
1.23 μM
Compound: Methotrexate
|
Antiproliferative activity against LPS-induced- mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against LPS-induced- mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay
|
[PMID: 38070351] |
| RPMI-8226 | IC50 |
33 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against RPMI-8226 leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against RPMI-8226 leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| RT-4 | IC50 |
0.04 μM
Compound: Methotrexate
|
Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining
Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| RXF 393 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against RXF-393 kidney cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against RXF-393 kidney cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SCC-15 | IC50 |
0.038 μM
Compound: MTX
|
Inhibitory concentration against growth of SCC15 cell line
Inhibitory concentration against growth of SCC15 cell line
|
[PMID: 3385730] |
| SCC-15 | IC50 |
0.58 μM
Compound: MTX
|
Inhibitory concentration against growth of SCC15/R1 cell line
Inhibitory concentration against growth of SCC15/R1 cell line
|
[PMID: 3385730] |
| SCC-25 | IC50 |
0.0075 μM
Compound: MTX
|
Inhibitory concentration against growth of SCC25 cell line
Inhibitory concentration against growth of SCC25 cell line
|
[PMID: 3385730] |
| SCC-25 | IC50 |
0.15 μM
Compound: MTX
|
Inhibitory concentration against growth of SCC25/R1 cell line
Inhibitory concentration against growth of SCC25/R1 cell line
|
[PMID: 3385730] |
| SCC-25 | IC50 |
7.5 nM
Compound: MTX
|
Tested for inhibitory concentration against human SCC25 cell line
Tested for inhibitory concentration against human SCC25 cell line
|
[PMID: 8035423] |
| SCC-25 | IC50 |
27 nM
Compound: MTX (1)
|
In vitro antitumor activity against SCC25 human head and neck squamous carcinoma cells containing 10% fetal bovine serum
In vitro antitumor activity against SCC25 human head and neck squamous carcinoma cells containing 10% fetal bovine serum
|
[PMID: 9022795] |
| SCC-7 | IC50 |
5.8 nM
Compound: MTX
|
Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line
Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line
|
[PMID: 8035423] |
| Sf21 | IC50 |
>1000 μM
Compound: Methotrexate
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
>1000 μM
Compound: Methotrexate
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| SF-268 | IC50 |
52 nM
Compound: MTX (1)
|
The IC50 value was measured on SF-268 cell line in CNS tumor type.
The IC50 value was measured on SF-268 cell line in CNS tumor type.
|
[PMID: 9022795] |
| SF-268 | IC50 |
52 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SF-268 CNS cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SF-268 CNS cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SF-295 | IC50 |
36 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SF-295 CNS cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SF-295 CNS cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SF-539 | IC50 |
35 nM
Compound: MTX (1)
|
The IC50 value was measured on SF-539 cell line in CNS tumor type.
The IC50 value was measured on SF-539 cell line in CNS tumor type.
|
[PMID: 9022795] |
| SF-539 | IC50 |
35 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SF-539 CNS cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SF-539 CNS cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SK-MEL-2 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SK-MEL-2 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SK-MEL-2 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SK-MEL-28 | IC50 |
0.01 μg/mL
Compound: ametropterin
|
Antitumor activity against human SK MEL28 cells
Antitumor activity against human SK MEL28 cells
|
[PMID: 10579858] |
| SK-MEL-28 | IC50 |
>1000 nM
Compound: MTX (1)
|
The IC50 value was measured on SKMEL-28 cell line in melanoma tumor type.
The IC50 value was measured on SKMEL-28 cell line in melanoma tumor type.
|
[PMID: 9022795] |
| SK-MEL-28 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SK-MEL28 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SK-MEL28 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SK-MEL-5 | IC50 |
87 nM
Compound: MTX (1)
|
The IC50 value was measured on SK-MEL-5 cell line in melanoma tumor type.
The IC50 value was measured on SK-MEL-5 cell line in melanoma tumor type.
|
[PMID: 9022795] |
| SK-MEL-5 | IC50 |
87 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SK-MEL-5 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SK-MEL-5 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SK-OV-3 | IC50 |
0.06 μM
Compound: MTX
|
Antiproliferative activity against human SKOV3 cells after 48 hrs
Antiproliferative activity against human SKOV3 cells after 48 hrs
|
[PMID: 23124219] |
| SNB-7 | IC50 |
>60 μg/mL
Compound: methotrexate
|
Growth inhibition of human SNB7 cells after 72 hrs
Growth inhibition of human SNB7 cells after 72 hrs
|
[PMID: 17569517] |
| SNB-75 | IC50 |
>1000 nM
Compound: MTX (1)
|
The IC50 value was measured on SNB-75 cell line in CNS tumor type.
The IC50 value was measured on SNB-75 cell line in CNS tumor type.
|
[PMID: 9022795] |
| SR | IC50 |
33 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against SR leukemia cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against SR leukemia cell lines (Human tumor cells )
|
[PMID: 9857098] |
| SW 1116 | IC50 |
2.49 μM
Compound: Methotrexate
|
Antitumor activity against human SW1116 cells assessed as reduction in cell viability incubated for overnight by MTT assay
Antitumor activity against human SW1116 cells assessed as reduction in cell viability incubated for overnight by MTT assay
|
[PMID: 31260892] |
| SW480 | IC50 |
0.015 μM
Compound: MTX
|
Inhibition of cell growth against SW480 human gastrointestinal adenocarcinoma cell lines in vitro
Inhibition of cell growth against SW480 human gastrointestinal adenocarcinoma cell lines in vitro
|
[PMID: 3612694] |
| SW480 | IC50 |
0.015 μM
Compound: 1a
|
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by SW480 assay
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by SW480 assay
|
[PMID: 3968685] |
| SW480 | IC50 |
0.015 μM
Compound: MTX
|
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells SW480
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells SW480
|
[PMID: 6694171] |
| SW-620 | IC50 |
0.013 μM
Compound: MTX
|
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay in presence of leucovorin
Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay in presence of leucovorin
|
[PMID: 27017552] |
| SW-620 | IC50 |
0.022 μM
Compound: MTX
|
Antiproliferative activity against human SW620 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay
Antiproliferative activity against human SW620 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay
|
[PMID: 28830032] |
| SW-620 | IC50 |
13.1 nM
Compound: MTX
|
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31200235] |
| SW-620 | IC50 |
33 nM
Compound: MTX (1)
|
The IC50 value was measured on SW-620 cell line in colon tumor type.
The IC50 value was measured on SW-620 cell line in colon tumor type.
|
[PMID: 9022795] |
| T47D | IC50 |
0.16 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human T47D cells after 48 hrs by MTT assay
Cytotoxicity against human T47D cells after 48 hrs by MTT assay
|
[PMID: 20846760] |
| T47D | IC50 |
64.4 nM
Compound: Methotrexate
|
Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 23468529] |
| T47D | IC50 |
15 μM
Compound: 3; MTX
|
Cytotoxicity against human T47D cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
Cytotoxicity against human T47D cells expressing Y1R assessed as reduction in cell viability treated for 8 hrs followed by culturing in proliferation medium for 72 hrs by resazurin assay
|
[PMID: 26985967] |
| T47D | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against T-47D breast cancer cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against T-47D breast cancer cell lines (Human tumor cells )
|
[PMID: 9857098] |
| T47D | IC50 |
0.16 μg/mL
Compound: Methotrexate
|
Cytotoxicity against human T47D cells after 48 hrs by MTT assay
Cytotoxicity against human T47D cells after 48 hrs by MTT assay
|
10.1007/s00044-013-0773-3 |
| T-cell | IC50 |
6.1 ng/mL
Compound: MTX
|
Inhibitory activity against Con A-stimulated T cell proliferation.
Inhibitory activity against Con A-stimulated T cell proliferation.
|
[PMID: 9379448] |
| TK-10 | IC50 |
>1000 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against TK-10 kidney cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against TK-10 kidney cell lines (Human tumor cells )
|
[PMID: 9857098] |
| U-251 | IC50 |
63 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against U251 CNS cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against U251 CNS cell lines (Human tumor cells )
|
[PMID: 9857098] |
| U-373MG ATCC | IC50 |
12 nM
Compound: MTX
|
Cytotoxic activity was evaluated against U373MG tumor cells
Cytotoxic activity was evaluated against U373MG tumor cells
|
[PMID: 8632413] |
| U-87MG ATCC | IC50 |
22 nM
Compound: MTX
|
Cytotoxic activity was evaluated against U87MG tumor cells
Cytotoxic activity was evaluated against U87MG tumor cells
|
[PMID: 8632413] |
| UACC-257 | IC50 |
790 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against UACC-257 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against UACC-257 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| UACC-62 | IC50 |
28 nM
Compound: MTX (1)
|
The IC50 value was measured on UACC-62 cell line in melanoma tumor type.
The IC50 value was measured on UACC-62 cell line in melanoma tumor type.
|
[PMID: 9022795] |
| UACC-62 | IC50 |
28 nM
Compound: MTX
|
Compound was evaluated for in vitro activity against UACC-62 Melanoma cell lines (Human tumor cells )
Compound was evaluated for in vitro activity against UACC-62 Melanoma cell lines (Human tumor cells )
|
[PMID: 9857098] |
| UO-31 | IC50 |
191 nM
Compound: MTX (1)
|
The IC50 value was measured on UO-31 cell line in renal tumor type.
The IC50 value was measured on UO-31 cell line in renal tumor type.
|
[PMID: 9022795] |
| Vero | IC50 |
9.2 nM
Compound: MTX
|
Cytotoxic Activity was evaluated against Vero tumor cells
Cytotoxic Activity was evaluated against Vero tumor cells
|
[PMID: 8632413] |
| W256 | ED50 |
0.02 μM
Compound: methotrexate
|
Cytotoxic activity against the Walker 256 carcinosarcoma in rats
Cytotoxic activity against the Walker 256 carcinosarcoma in rats
|
[PMID: 6928967] |
| WiDr | IC50 |
0.025 μM
Compound: MTX
|
Inhibition of cell growth against WIDR human gastrointestinal adenocarcinoma cell lines in vitro
Inhibition of cell growth against WIDR human gastrointestinal adenocarcinoma cell lines in vitro
|
[PMID: 3612694] |
| WiDr | IC50 |
0.025 μM
Compound: 1a
|
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by WIDR assay
Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by WIDR assay
|
[PMID: 3968685] |
| WiDr | IC50 |
0.025 μM
Compound: MTX
|
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells WIDR
In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells WIDR
|
[PMID: 6694171] |
| WIL2 | IC50 |
0.0038 μM
Compound: MTX
|
Inhibitory activity against dihydrofolate reductase (DHFR) obtained from human WIL2 cells
Inhibitory activity against dihydrofolate reductase (DHFR) obtained from human WIL2 cells
|
[PMID: 3339615] |
| ZR-75-1 | IC50 |
>60 μg/mL
Compound: methotrexate
|
Growth inhibition of human ZR-75-1 cells after 72 hrs
Growth inhibition of human ZR-75-1 cells after 72 hrs
|
[PMID: 17569517] |
| ZR-75-1 | IC50 |
66 nM
Compound: Methotrexate
|
Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 23468529] |
In Vitro
Methotrexate at high concentrations stimulates adenosine secretion of endothelial cells, fibroblasts and peripheral blood monocytes, and this effect is amplified under metabolic stress; it further modulates macrophage function through adenosine and suppresses peripheral blood mononuclear cells from producing immunoglobulins, rheumatoid factors and spontaneous IL-8, which may be attributed to the reduction of intracellular polyamine levels[1].
Methotrexate (MTX) (0.01-100 μM; 72 h) induces dose-dependent cytotoxicity in primary mouse alveolar epithelial cells (MAEC) and primary mouse lung fibroblasts (MLF)[4].
Methotrexate (1 μM; 12-48 h) induces significant time-dependent apoptosis in primary mouse alveolar epithelial cells (MAEC), but exerts no significant pro-apoptotic effect on primary mouse lung fibroblasts (MLF) under the same conditions[4].
Methotrexate (0.5-5 μM; 24 h) dose-dependently enhances cytotoxicity and reduces cell viability in FM3A breast cancer cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Methotrexate (low dose; intraperitoneal injection; weekly) exerts anti-inflammatory effects by enhancing the extracellular adenosine signaling pathway mediated by ADORA2A and ADORA3 receptors, reducing leukocyte accumulation and TNF-α accumulation at inflammatory sites, while inducing liver fibrosis in hepatotoxin models via this pathway[2].
Methotrexate (3 mg/kg; p.o.; daily; days 21-35) induces pulmonary fibrosis in male C57BL/6J mice in a time-dependent manner[4].
Methotrexate (40 mg/kg; i.p.; single dose) induces hippocampal dysfunction in both FM3A-inoculated breast cancer mice and tumor-free healthy mice, including significant depression-like behaviors, cognitive impairment, reduced hippocampal neurogenesis, and upregulated expression of pro-inflammatory enzymes[5].
Methotrexate (MTX) (2 mg/kg; i.p.; once weekly for 5 consecutive weeks) is effective against Freund's complete adjuvant-induced arthritis[6].
Methotrexate (1 mg/kg, intraperitoneal injection, once a week for 5 weeks) combined with Curcumin (HY-N0005, 30 mg/kg and 100 mg/kg, intraperitoneal injection, three times a week for 5 weeks) exhibits remarkable anti-arthritic effects and protective activity against hematotoxicity[6].
Methotrexate (3 mg/kg; p.o.; daily; days 21-35) induces pulmonary fibrosis in male C57BL/6J mice in a time-dependent manner[4].
Methotrexate (40 mg/kg; i.p.; single dose) induces hippocampal dysfunction in both FM3A-inoculated breast cancer mice and tumor-free healthy mice, including significant depression-like behaviors, cognitive impairment, reduced hippocampal neurogenesis, and upregulated expression of pro-inflammatory enzymes[5].
Methotrexate (MTX) (2 mg/kg; i.p.; once weekly for 5 consecutive weeks) is effective against Freund's complete adjuvant-induced arthritis[6].
Methotrexate (1 mg/kg, intraperitoneal injection, once a week for 5 weeks) combined with Curcumin (HY-N0005, 30 mg/kg and 100 mg/kg, intraperitoneal injection, three times a week for 5 weeks) exhibits remarkable anti-arthritic effects and protective activity against hematotoxicity[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 59-05-2
-
Appearance Solid
-
Masse moléculaire 454.44
-
Formule C20H22N8O5
-
Color Light yellow to yellow
-
SMILES
NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)=N1
-
Synonyms
Amethopterin; CL14377; WR19039
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (80)
All
Cell Imaging/StainingCell Proliferation/Viability AssayRT-PCRCell Migration/Invasion Assay
Journal Impact Factor
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
2024 Apr 29;23(1):86. PMID: 38685067 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Adv Mater
3D Bioprinted Human Synovium-Cartilage Models Mimic Rheumatoid Arthritis Microenvironment and Recapitulate In Vivo Therapeutic Responses. [Abstract]2025 Dec 12:e13952. PMID: 41388589 -
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Nat Commun
ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation. [Abstract]2025 Feb 28;16(1):2071. PMID: 40021646
Methotrexate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. Cells were stained with γH2AX.
Methotrexate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. The expression of SASP genes was analysed by qRT–PCR.
-
J Adv Res
Columbianadin ameliorates rheumatoid arthritis by attenuating synoviocyte hyperplasia through targeted vimentin to inhibit the VAV2/Rac-1 signaling pathway. [Abstract]2025 Aug:74:609-620. PMID: 39369957
Methotrexate purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell viability of MH7A cells treated with methotrexate (1 μM) for 24 h was determined by the CCK-8 method.
Methotrexate purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell migration of MH7A cells treated with methotrexate (1 μM) for 24 h.
-
Redox Biol
Therapeutic potential of monomethyl fumarate and aluminum ion combination in alleviating inflammation and oxidative stress in psoriasis. [Abstract]2025 Feb:79:103482. PMID: 39736200 -
J Nanobiotechnology
EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy. [Abstract]2024 Mar 3;22(1):89. PMID: 38433190 -
J Exp Clin Cancer Res
OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway. [Abstract]2024 Dec 26;43(1):330. PMID: 39721999 -
J Clin Invest
Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations. [Abstract]2023 Jul 3;133(13):e169993. PMID: 37252797
Methotrexate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
A CellTiter-Glo® luminescent cell viability assay was performed on CAL51 WT and MLL4 KO cells, which were treated with 0, 0.04, or 0.4 μM Methotrexate (MTX) in the presence of H2O, 50 μM thymidine, or 50 μM inosine.
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Mol Biomed
A single non-coding SNP in FPGS modulates folate drug efficacy in acute lymphoblastic leukemia: data-driven exploration and experimental validation. [Abstract]2025 Nov 21;6(1):114. PMID: 41269429 -
Cell Death Dis
Downregulation of ZFP36L1 contributes to methotrexate resistance in osteosarcoma through enhanced NHEJ DNA repair mechanisms. [Abstract]2025 Nov 24;16(1):852. PMID: 41285712 -
Cell Death Dis
2025 Nov 24;16(1):856. PMID: 41285805 -
Cell Death Dis
Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. [Abstract]2024 May 20;15(5):349. PMID: 38769167 -
Cell Death Dis
2020 Nov 12;11(11):976. PMID: 33184290 -
Small
DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment. [Abstract]2022 Jul;18(30):e2202337. PMID: 35780479 -
Phytomedicine
Paeoniflorin derivative ameliorates methotrexate resistance in treating rheumatoid arthritis through targeting GRK2-A2AAR axis. [Abstract]2026 Jan:150:157731. PMID: 41447845 -
Phytomedicine
Geniposide alleviates VEGF-induced angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1 translocation. [Abstract]2022 Jun;100:154068. PMID: 35358930 -
J Pharm Anal
A highly efficient protein corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers. [Abstract]2022 Dec;12(6):879-888. PMID: 36605576 -
Acta Biomater
2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907 -
Acta Pharmacol Sin
Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. [Abstract]2025 Jun;46(6):1733-1741. PMID: 39939802 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Biomater Res
Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy. [Abstract]2025 Sep 3:29:0245. PMID: 40908968 -
EMBO Mol Med
Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway. [Abstract]2025 Oct 13. PMID: 41083822 -
EMBO Mol Med
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. [Abstract]2022 Mar 7;14(3):e14552. PMID: 35174975 -
Cell Rep
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]2025 Mar 25;44(4):115466. PMID: 40138312 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Sci Signal
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]2024 Nov 26;17(864):eadp1375. PMID: 39591412 -
J Ethnopharmacol
Kai-Xin-San alleviates Alzheimer's disease by targeting the DHFR-mediated folate-mitochondrial axis. [Abstract]2026 Apr 24:361:121230. PMID: 41548619 -
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Cells
Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [Abstract]2026 Jun 11;15(12):1070. PMID: 42346097 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195 -
Eur J Pharmacol
Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathway. [Abstract]2023 Dec 15:961:176162. PMID: 37951487 -
Int Immunopharmacol
Isorhapontigenin suppresses inflammation, proliferation and aggressiveness of rheumatoid arthritis fibroblast-like synoviocytes by targeting farnesyl diphosphate synthase. [Abstract]2025 Jun 26:159:114894. PMID: 40412131 -
Int Immunopharmacol
Regulation of P-glycoprotein through CaMKII/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine. [Abstract]2025 May 27:156:114735. PMID: 40294472 -
Int Immunopharmacol
Cornuside alleviates psoriasis-like skin lesions in mice by relieving inflammatory effects. [Abstract]2024 Jun 15:134:112183. PMID: 38705031 -
Int Immunopharmacol
Herbal compound cepharanthine attenuates inflammatory arthritis by blocking macrophage M1 polarization. [Abstract]2023 Nov 15;125(Pt B):111175. PMID: 37976601 -
Int Immunopharmacol
Iso-seco-tanapartholide induces p62 covalent oligomerization to activate KEAP1-NRF2 redox pathway in rheumatoid arthritis. [Abstract]2023 Feb:115:109689. PMID: 36621330 -
Arthritis Res Ther
Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases. [Abstract]2022 Jan 19;24(1):27. PMID: 35045889 -
ACS Omega
ROS-Scavenging Bamboo-Derived Carbon Dot-Methotrexate Nanocomposite Ameliorates Rheumatoid Arthritis through Dual Therapeutic Mechanisms. [Abstract]2026 Jan 21;11(4):5853-5864. PMID: 41658163 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Toxicology
Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects. [Abstract]2020 May 15:437:152445. PMID: 32259555 -
Eur J Pharm Sci
Repurposing of FDA-approved drugs by targeting SIRT2 to alleviate inflammatory response and kidney injury. [Abstract]2025 Nov 1:214:107296. PMID: 41022315 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Mediators Inflamm
Peptide BG From Bitter Gourd (Momordica Charantia) Improves Adjuvant-Induced Arthritis by Modulating the Necroptosis/Neutrophil Extracellular Traps/Inflammation Axis and the Gut Microbiota. [Abstract]2024 Dec 5:2024:1995952. PMID: 39669913 -
Sci Rep
High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway. [Abstract]2024 Oct 31;14(1):26224. PMID: 39482401 -
Sci Rep
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. [Abstract]2018 Jun 21;8(1):9472. PMID: 29930256 -
Cancers (Basel)
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]2022 Oct 19;14(20):5127. PMID: 36291909 -
Cancers
2019 Oct 25;11(11):1654. PMID: 31717700 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
Antiviral Res
Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity. [Abstract]2026 Jun:250:106417. PMID: 42025967 -
Lung
Disulfiram Alleviates MTX-Induced Pulmonary Fibrosis by Inhibiting EMT in Type 2 Alveolar Epithelial Cells. [Abstract]2024 Nov 27;203(1):4. PMID: 39601871 -
Antimicrob Agents Chemother
Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase. [Abstract]2026 Jul;70(7):e0196025. PMID: 42206914 -
Chem Res Toxicol
Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships. [Abstract]2025 Feb 17;38(2):281-295. PMID: 39899883 -
J Biol Chem
A technique for delineating the unfolding requirements for substrate entry into retrotranslocons during endoplasmic reticulum-associated degradation. [Abstract]2019 Dec 27;294(52):20084-20096. PMID: 31748412 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Mol Immunol
Methotrexate loaded extracellular vesicles attenuate periodontitis by suppressing ACSL1 and promoting anti-inflammatory macrophage. [Abstract]2025 Apr 16:182:83-95. PMID: 40245705 -
Dis Model Mech
A Drosophila chemical screen reveals targeting MEK and DGKa mitigates Ras-driven polarity-impaired tumour growth. [Abstract]2023 Mar 1;16(3):dmm049769. PMID: 36861754 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Micromachines
2021 Jun 10;12(6):681. PMID: 34200752 -
Biochem Biophys Rep
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation. [Abstract]2021 Nov 26:28:101177. PMID: 34877414 -
-
Int J Immunopathol Pharmacol
Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice. [Abstract]2025 Jan-Dec:39:3946320251348715. PMID: 40518910 -
Anticancer Res
Loss of Malignancy of Super-Methotrexate-resistant Osteosarcoma Cells Is Associated With an Increase of Methylated Histone Marks H3K9me3 and H3K27me3. [Abstract]2024 Oct;44(10):4213-4218. PMID: 39348992 -
Anticancer Res
Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. [Abstract]2024 Jul;44(7):2787-2792. PMID: 38925854 -
-
-
-
-
-
-
Biomed Pharmacother
Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1. [Abstract]2024 Sep:178:117167. PMID: 39032285 -
-
-
-
Oncotarget
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]2017 Dec 2;8(68):112313-112329. PMID: 29348827 -
Solvant et solubilité
In Vitro:
DMSO : ≥ 50 mg/mL (110.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
View the Complete Stock Solution Preparation Table
Preparing Stock Solutions
View the Complete Stock Solution Preparation Table
Concentration
Solvent
Mass
1 mg
5 mg
10 mg
Concentration
Solvent
Mass
1 mM
2.2005 mL
11.0026 mL
22.0051 mL
5 mM
0.4401 mL
2.2005 mL
4.4010 mL
10 mM
0.2201 mL
1.1003 mL
2.2005 mL
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Calculateur de molarité
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Calculateur de dilution
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
Stock Solution Working Solution
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact
Method for preparing in vivo working solution for animal experiments:
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Saline
.
Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Cell Assay[1]
Each cell line is studied in growth inhibition experiments using 96-well microtiter plates. As antifols are schedule dependent, preliminary experiments are aimed at defining the longest duration of exposure that would allow for continuous logarithmic phase growth of cells without changing of the culture media while maintaining a linear relationship between SRB optical density and cell number. Twenty-four hours after cell plating, the cell lines are exposed to the antifol for 120 h (three replicates per experiment). To ensure that a complete sigmoidal survival-concentration curve could be observed, the following drug concentrations are studied: Methotrexate (0.002-5 μM), AMT (0.0001-1 μM), PXD (0.0003-10 μM), TLX (0.0002-0.5 μM). Experiments are repeated at least twice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[2]
Mice[2]
The combination of bioactive phytochemicals is administered one week prior to the Methotrexate exposure. Treatment group I: mice are given a combination of green tea polyphenols and eleutherosides from Siberian ginseng (0.2 mL/10 g, i.g. once daily) for 15 days, and a single dose of Methotrexate (2 mg/kg, i.p. once daily) is added on the 8th day. Treatment group II: mice are given a combination of grape seed proanthocyanidins and eleutherosides from Siberian ginseng for 15 days, and Methotrexate is administered on the 8th day in a similar manner. Model group: animals received distilled water instead of bioactive phytochemicals combinations for 15 days and the same Methotrexate protocol applied to this group on the 8th day. Control group: mice are given distilled water through 15 days and physiological saline instead of Methotrexate is administered on the 8th day in a similar manner. Twelve hours after the final doses, the animals are euthanized by cervical dislocation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
Select Batch:
Pureté:
99.98%
Assay:
99.98%
ee.:
99.98%
-
Fiche technique (279 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cronstein BN, et al. The mechanism of action of methotrexate. Rheumatic diseases clinics of North America. 1997 Nov;23(4):739-55. [Content Brief]
[2]. Bedoui Y, et al. Methotrexate an Old Drug with New Tricks. International journal of molecular sciences. 2019 Oct 10;20(20):5023. [Content Brief]
[4]. Ohbayashi M, et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. The Journal of toxicological sciences. 2010 Oct;35(5):653-61. [Content Brief]
[5]. Yang M, et al. Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain research bulletin. 2012 Oct 01;89(1-2):50-6. [Content Brief]
[6]. Banji D, et al. Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats. Indian J Pharmacol. 2011 Sep;43(5):546-50. [Content Brief]
View More
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2005 mL | 11.0026 mL | 22.0051 mL | 55.0128 mL |
| 5 mM | 0.4401 mL | 2.2005 mL | 4.4010 mL | 11.0026 mL | |
| 10 mM | 0.2201 mL | 1.1003 mL | 2.2005 mL | 5.5013 mL | |
| 15 mM | 0.1467 mL | 0.7335 mL | 1.4670 mL | 3.6675 mL | |
| 20 mM | 0.1100 mL | 0.5501 mL | 1.1003 mL | 2.7506 mL | |
| 25 mM | 0.0880 mL | 0.4401 mL | 0.8802 mL | 2.2005 mL | |
| 30 mM | 0.0734 mL | 0.3668 mL | 0.7335 mL | 1.8338 mL | |
| 40 mM | 0.0550 mL | 0.2751 mL | 0.5501 mL | 1.3753 mL | |
| 50 mM | 0.0440 mL | 0.2201 mL | 0.4401 mL | 1.1003 mL | |
| 60 mM | 0.0367 mL | 0.1834 mL | 0.3668 mL | 0.9169 mL | |
| 80 mM | 0.0275 mL | 0.1375 mL | 0.2751 mL | 0.6877 mL | |
| 100 mM | 0.0220 mL | 0.1100 mL | 0.2201 mL | 0.5501 mL |
Methotrexate Related Classifications
HY-14519 Related Classifications
Powered by Bioz
Keywords
- Methotrexate
- 59-05-2
- Amethopterin
- CL14377
- WR19039
- CL14377
- CL 14377
- CL-14377
- WR19039
- WR 19039
- WR-19039
- Antifolate
- Dihydrofolate reductase (DHFR)
- NO Synthase
- COX
- Interleukin Related
- tetrahydrofolate
- AICAR transformylase
- ROS
- COX-2
- iNOS
- HMGB1 alarmin
- purine/pyrimidine synthesis
- dihydrofolate reductase
- methotrexate-polyglutamates
- leukotriene B4
- Inhibitor
- inhibitor
- inhibit